Cover
Cover | 6 Months Ended |
Jun. 30, 2022 shares | |
Cover [Abstract] | |
Document Type | 10-Q |
Document Quarterly Report | true |
Document Period End Date | Jun. 30, 2022 |
Document Transition Report | false |
Entity File Number | 333-190916 |
Entity Registrant Name | HEALTHCARE REALTY HOLDINGS, L.P. |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 20-4738347 |
Entity Address, Address Line One | 3310 West End Avenue, |
Entity Address, Address Line Two | Suite 700 |
Entity Address, City or Town | Nashville, |
Entity Address, State or Province | TN |
Entity Address, Postal Zip Code | 37203 |
City Area Code | (615) |
Local Phone Number | 269-8175 |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | false |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 0 |
Entity Central Index Key | 0001495491 |
Amendment Flag | false |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Year Focus | 2022 |
Document Fiscal Period Focus | Q2 |
Title of 12(b) Security | N/A |
Trading Symbol | N/A |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Real estate investments: | ||
Land | $ 648,394 | $ 640,382 |
Building and improvements | 6,774,818 | 6,688,516 |
Lease intangibles | 382,738 | 404,714 |
Construction in progress | 15,252 | 32,685 |
Real estate investments, gross | 7,821,202 | 7,766,297 |
Accumulated depreciation and amortization | (1,699,546) | (1,598,468) |
Real estate investments, net | 6,121,656 | 6,167,829 |
Assets held for sale, net | 0 | 27,070 |
Investment in unconsolidated joint venture | 62,070 | 62,834 |
Cash and cash equivalents | 29,714 | 52,353 |
Restricted cash | 4,559 | 4,716 |
Receivables and other assets, net | 360,433 | 334,941 |
Right-of-use assets - operating leases, net | 227,603 | 229,226 |
Other intangibles, net | 9,315 | 10,720 |
Total assets | 6,815,350 | 6,889,689 |
Liabilities: | ||
Debt | 3,094,643 | 3,028,122 |
Accounts payable and accrued liabilities | 171,673 | 198,078 |
Liabilities of assets held for sale | 0 | 262 |
Derivative financial instruments - interest rate swaps | 0 | 5,069 |
Security deposits, prepaid rent and other liabilities | 82,071 | 86,225 |
Lease liabilities - operating leases | 196,991 | 196,286 |
Intangible liabilities, net | 28,671 | 31,331 |
Total liabilities | 3,574,049 | 3,545,373 |
Commitments and contingencies | ||
Partners’ Capital: | ||
Limited partners’ capital, 4,050,493 and 4,142,408 OP Units issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 82,369 | 86,442 |
General partners’ capital, 229,072,922 and 228,879,846 OP Units issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 3,158,932 | 3,257,874 |
Total partners’ capital | 3,241,301 | 3,344,316 |
Total liabilities and equity/partners' capital | $ 6,815,350 | $ 6,889,689 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares | Jun. 30, 2022 | Dec. 31, 2021 |
Partners’ Capital: | ||
Limited partner's capital, units issued (in shares) | 4,050,493 | 4,142,408 |
Limited partner's capital, units outstanding (in shares) | 4,050,493 | 4,142,408 |
General partner's capital, units issued (in shares) | 229,072,922 | 228,879,846 |
General partner's capital, units outstanding (in shares) | 229,072,922 | 228,879,846 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Revenues: | ||||
Rental income | $ 198,284 | $ 188,494 | $ 398,527 | $ 379,844 |
Interest and other operating income | 1,849 | 121 | 3,608 | 264 |
Total revenues | 200,133 | 188,615 | 402,135 | 380,108 |
Expenses: | ||||
Rental | 63,373 | 57,409 | 129,257 | 116,988 |
General and administrative | 14,243 | 10,929 | 26,691 | 21,489 |
Merger-related costs | 5,107 | 0 | 11,125 | 0 |
Transaction | 97 | 66 | 241 | 162 |
Depreciation and amortization | 75,051 | 74,977 | 150,437 | 151,251 |
Interest expense | 24,760 | 23,133 | 48,700 | 46,119 |
Impairment | 0 | 16,825 | 0 | 16,825 |
Total expenses | 182,631 | 183,339 | 366,451 | 352,834 |
Gain (loss) on sale of real estate, net | 0 | 32,753 | (4) | 32,753 |
Loss on extinguishment of debt, net | (3,615) | 0 | (3,615) | 0 |
Income from unconsolidated joint venture | 401 | 406 | 801 | 798 |
Other income | 134 | 304 | 222 | 307 |
Net income | 14,422 | 38,739 | 33,088 | 61,132 |
Net income attributable to non-controlling interests | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders/unitholders | $ 14,422 | $ 38,739 | $ 33,088 | $ 61,132 |
Earnings per common share - basic | ||||
Net income attributable to common stockholders/unitholders (in dollars per share) | $ 0.06 | $ 0.17 | $ 0.14 | $ 0.28 |
Earnings per common share - diluted | ||||
Net income attributable to common stockholders/unitholders (in dollars per share) | $ 0.06 | $ 0.17 | $ 0.14 | $ 0.28 |
Weighted average common shares outstanding: | ||||
Basic (in shares/units) | 233,125 | 222,326 | 233,086 | 222,297 |
Diluted (in shares/units) | 233,125 | 222,326 | 233,086 | 222,297 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 14,422 | $ 38,739 | $ 33,088 | $ 61,132 |
Other comprehensive income | ||||
Change in unrealized gains on cash flow hedges | 4,085 | 1,523 | 12,902 | 4,315 |
Total other comprehensive income | 4,085 | 1,523 | 12,902 | 4,315 |
Total comprehensive income | 18,507 | 40,262 | 45,990 | 65,447 |
Comprehensive income attributable to non-controlling interests | 0 | 0 | 0 | 0 |
Total comprehensive income (loss) attributable to common stockholders/unitholders | $ 18,507 | $ 40,262 | $ 45,990 | $ 65,447 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS' CAPITAL - USD ($) shares in Thousands, $ in Thousands | Total | General Partners’ Capital | Limited Partners’ Capital |
Balance as of beginning of period at Dec. 31, 2020 | $ 3,234,919 | $ 3,174,509 | $ 60,410 |
Balance as of beginning of period (in shares) at Dec. 31, 2020 | 218,578 | 3,520 | |
Increase (Decrease) in Partners' Capital [Roll Forward] | |||
Share-based award transactions, net | 3,337 | $ 3,337 | |
Share-based award transactions, net (in shares) | 354 | ||
Redemption and cancellation of general partner units (in shares) | (119) | ||
Redemption and cancellation of general partner OP Units | (3,248) | $ (3,248) | |
Redemption of limited partner OP Units and other (in shares) | 11 | (11) | |
Redemption of limited partner OP Units and other | 0 | $ 255 | $ (255) |
Distributions declared | (71,206) | (70,023) | (1,183) |
Net income | 22,393 | 22,030 | 363 |
Other comprehensive income (loss) | 2,792 | 2,748 | 44 |
Balance as of end of period at Mar. 31, 2021 | 3,188,987 | $ 3,129,608 | $ 59,379 |
Balance as of end of period (in shares) at Mar. 31, 2021 | 218,824 | 3,509 | |
Balance as of beginning of period at Dec. 31, 2020 | 3,234,919 | $ 3,174,509 | $ 60,410 |
Balance as of beginning of period (in shares) at Dec. 31, 2020 | 218,578 | 3,520 | |
Increase (Decrease) in Partners' Capital [Roll Forward] | |||
Net income | 61,132 | ||
Other comprehensive income (loss) | 4,315 | ||
Balance as of end of period at Jun. 30, 2021 | 3,159,888 | $ 3,101,324 | $ 58,564 |
Balance as of end of period (in shares) at Jun. 30, 2021 | 218,826 | 3,496 | |
Balance as of beginning of period at Mar. 31, 2021 | 3,188,987 | $ 3,129,608 | $ 59,379 |
Balance as of beginning of period (in shares) at Mar. 31, 2021 | 218,824 | 3,509 | |
Increase (Decrease) in Partners' Capital [Roll Forward] | |||
Issuance of general partner OP Units (in shares) | 0 | ||
Issuance of general partner OP Units | 0 | $ 0 | |
Share-based award transactions, net | 2,065 | $ 2,065 | |
Share-based award transactions, net (in shares) | (6) | ||
Redemption and cancellation of general partner units (in shares) | (5) | ||
Redemption and cancellation of general partner OP Units | (129) | $ (129) | |
Redemption of limited partner OP Units and other (in shares) | 13 | (13) | |
Redemption of limited partner OP Units and other | 0 | $ 291 | $ (291) |
Distributions declared | (71,297) | (70,019) | (1,278) |
Net income | 38,739 | 38,011 | 728 |
Other comprehensive income (loss) | 1,523 | 1,497 | 26 |
Balance as of end of period at Jun. 30, 2021 | 3,159,888 | $ 3,101,324 | $ 58,564 |
Balance as of end of period (in shares) at Jun. 30, 2021 | 218,826 | 3,496 | |
Balance as of beginning of period at Dec. 31, 2021 | 3,344,316 | $ 3,257,874 | $ 86,442 |
Balance as of beginning of period (in shares) at Dec. 31, 2021 | 228,880 | 4,142 | |
Increase (Decrease) in Partners' Capital [Roll Forward] | |||
Share-based award transactions, net | 2,024 | $ 2,024 | |
Share-based award transactions, net (in shares) | 154 | ||
Redemption and cancellation of general partner units (in shares) | (50) | ||
Redemption and cancellation of general partner OP Units | (1,640) | $ (1,640) | |
Redemption of limited partner OP Units and other (in shares) | 92 | (92) | |
Redemption of limited partner OP Units and other | 0 | $ 2,065 | $ (2,065) |
Distributions declared | (75,816) | (74,443) | (1,373) |
Net income | 18,666 | 18,315 | 351 |
Other comprehensive income (loss) | 8,817 | 8,768 | 49 |
Balance as of end of period at Mar. 31, 2022 | 3,296,367 | $ 3,212,963 | $ 83,404 |
Balance as of end of period (in shares) at Mar. 31, 2022 | 229,076 | 4,050 | |
Balance as of beginning of period at Dec. 31, 2021 | 3,344,316 | $ 3,257,874 | $ 86,442 |
Balance as of beginning of period (in shares) at Dec. 31, 2021 | 228,880 | 4,142 | |
Increase (Decrease) in Partners' Capital [Roll Forward] | |||
Net income | 33,088 | ||
Other comprehensive income (loss) | 12,902 | ||
Balance as of end of period at Jun. 30, 2022 | 3,241,301 | $ 3,158,932 | $ 82,369 |
Balance as of end of period (in shares) at Jun. 30, 2022 | 229,073 | 4,050 | |
Balance as of beginning of period at Mar. 31, 2022 | 3,296,367 | $ 3,212,963 | $ 83,404 |
Balance as of beginning of period (in shares) at Mar. 31, 2022 | 229,076 | 4,050 | |
Increase (Decrease) in Partners' Capital [Roll Forward] | |||
Share-based award transactions, net | 2,191 | $ 2,191 | |
Share-based award transactions, net (in shares) | (3) | ||
Redemption and cancellation of general partner OP Units | (4) | $ (4) | |
Distributions declared | (75,760) | (74,445) | $ (1,315) |
Net income | 14,422 | 14,168 | 254 |
Other comprehensive income (loss) | 4,085 | 4,059 | 26 |
Balance as of end of period at Jun. 30, 2022 | $ 3,241,301 | $ 3,158,932 | $ 82,369 |
Balance as of end of period (in shares) at Jun. 30, 2022 | 229,073 | 4,050 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS' CAPITAL (Parenthetical) - $ / shares | 3 Months Ended | |||
Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | |
Statement of Stockholders' Equity [Abstract] | ||||
Dividends declared (in dollars per share) | $ 0.325 | $ 0.325 | $ 0.320 | $ 0.320 |
CONDENSED CONSOLIDATED STATEM_5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Cash flows from operating activities: | ||
Net income | $ 33,088 | $ 61,132 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 142,174 | 142,062 |
Share-based compensation expense | 4,216 | 5,402 |
Income from unconsolidated joint venture | (801) | (798) |
Distributions from unconsolidated joint venture | 1,565 | 1,565 |
Impairment | 0 | 16,825 |
Loss (gain) on sale of real estate, net | 4 | (32,753) |
Loss on extinguishment of debt, net | 3,615 | 0 |
Changes in operating assets and liabilities: | ||
Receivables and other assets, net | (8,445) | 10,540 |
Accounts payable and accrued liabilities | (22,188) | (8,552) |
Security deposits, prepaid rent and other liabilities | (775) | (4,496) |
Net cash provided by operating activities | 152,453 | 190,927 |
Cash flows from investing activities: | ||
Investments in real estate | (25,855) | (50,628) |
Development of real estate | (22,478) | (33,983) |
Proceeds from the sale of real estate | 26,791 | 65,349 |
Capital expenditures | (54,954) | (53,471) |
Collection of real estate notes receivable | 0 | 15,405 |
Loan origination fees | 325 | 0 |
Advances on real estate notes receivable | (3,734) | (61,020) |
Net cash used in investing activities | (79,905) | (118,348) |
Cash flows from financing activities: | ||
Borrowings on unsecured revolving credit facility | 150,000 | 100,000 |
Payments on unsecured revolving credit facility | (85,000) | (55,000) |
Deferred financing costs | (7,154) | 0 |
Repurchase and cancellation of general partner units | (1,646) | (3,377) |
Distributions paid to general partner | (148,826) | (140,022) |
Distributions paid to limited partners and redeemable non-controlling interests | (2,718) | (2,607) |
Net cash used in financing activities | (95,344) | (101,006) |
Net change in cash, cash equivalents and restricted cash | (22,796) | (28,427) |
Cash, cash equivalents and restricted cash - beginning of period | 57,069 | 118,765 |
Cash, cash equivalents and restricted cash - end of period | $ 34,273 | $ 90,338 |
Organization and Description of
Organization and Description of Business | 6 Months Ended |
Jun. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business | Organization and Description of Business HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership, in an umbrella partnership, or “UPREIT” structure. HTA has qualified and intends to continue to be taxed as a REIT for federal income tax purposes under the applicable sections of the Internal Revenue Code of 1986, as amended. We own real estate primarily consisting of medical office buildings (“MOBs”) located on or adjacent to hospital campuses or in off-campus, community core outpatient locations across 32 states within the United States, and we lease space to tenants primarily consisting of health systems, research and academic institutions, and various sized physician practices. Through our full-service operating platform, we provide leasing, asset management, acquisitions, development and other related services for our properties. Our primary objective is to maximize stockholder value with growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing, building services and property management oversight; (ii) target accretive acquisitions and developments of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. Additionally, from time to time we consider, on an opportunistic basis, significant portfolio acquisitions that we believe fit our core business and we expect to enhance our existing portfolio. Merger with Healthcare Realty Trust Incorporated On July 20, 2022, HTA, HTALP, of which HTA is the sole general partner, HR Acquisition 2, LLC, a Maryland limited liability company and a direct, wholly owned subsidiary of HTA (“Merger Sub”), consummated a Merger with Healthcare Realty Trust Incorporated, a Maryland corporation (“HR”), pursuant to a definitive Agreement and Plan of Merger (the “Merger Agreement”) dated February 28, 2022, which was unanimously approved by the boards of directors of HTA and HR. Upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and into HR, with HR surviving the Merger (the “Merger”) and where HTALP became Healthcare Realty Holdings, L.P as the successor entity. Pursuant to the terms in the Merger Agreement, each outstanding share of Common Stock, $0.01 par value per share, of HR (“HR Common Stock”) was converted into the right to receive 1.0 (the “Exchange Ratio”) share of Class A Common Stock, $0.01 par value per share, of HTA (“Company Common Stock” and, such consideration, the “Merger Consideration”). Pursuant to the closing of the Merger and the other transactions contemplated therein, the holders of shares of Company Common Stock and OP Units issued and outstanding on July 19, 2022 received a special distribution in the amount of $4.82 in cash per share of Company Common Stock and OP Units held on such date (the “Special Distribution Payment”). Except where noted, the condensed consolidated financial statements for the quarter ended June 30, 2022, descriptions of HTA and HTALP, legal structure, employees, management, board of directors, customers, capitalization, risks and uncertainties, plans and objectives, strategy, and portfolio information solely relate to the Company prior to the consummation of the Merger without giving specific consideration to the combined entity post-Merger or plans of the Company’s management after the Merger. Refer to the “Explanatory Note” in the forepart of this Quarterly Report for further explanation of the description of the Company, relationship between HTA and HTALP, and the current and historical presentation of the financial statements and notes thereto contained herein. COVID-19 Pandemic |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the U.S. (“GAAP”) in all material respects and have been consistently applied in preparing our accompanying condensed consolidated financial statements. Basis of Presentation Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements. Interim Unaudited Financial Data Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements (i) do not include all information and footnotes required by GAAP for complete financial statements, and (ii) reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2021 Annual Report on Form 10-K. Principles of Consolidation The condensed consolidated financial statements include the accounts of our subsidiaries and consolidated joint venture arrangements. The portions of the HTALP operating partnership’s subsidiaries not owned by us are presented as non-controlling interests on the accompanying condensed consolidated balance sheets and statements of operations, condensed consolidated statements of comprehensive income, and condensed consolidated statements of changes in partners’ capital. As of both June 30, 2022 and December 31, 2021, there were approximately 4.1 million of OP Units issued and outstanding held by parties other than our sole general partner, HTA. VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Use of Estimates The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that effect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent asset and liabilities. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in adverse ways, and those estimates could be different under different assumptions or conditions. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of all highly liquid investments with a maturity of three months or less when purchased. Restricted cash is typically comprised of: (i) reserve accounts for property taxes, insurance, capital and tenant improvements; (ii) collateral accounts for debt and interest rate swaps; (iii) 1031 exchange funds; and (iv) deposits for future investments. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets to the amounts shown on the accompanying condensed consolidated statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 29,714 $ 19,796 Restricted cash 4,559 70,542 Total cash, cash equivalents and restricted cash $ 34,273 $ 90,338 Revenue Recognition Minimum annual rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). Differences between rental income recognized and amounts contractually due under the lease agreements are recorded as straight-line rent receivables. Tenant reimbursements, which is comprised of additional amounts recoverable from tenants for real estate taxes, common area maintenance and other certain operating expenses are recognized as revenue on a gross basis in the period in which the related recoverable expenses are incurred. We accrue revenue corresponding to these expenses on a quarterly basis to adjust recorded amounts to our best estimate of the final annual amounts to be billed. Subsequent to year-end, on a calendar year basis, we perform reconciliations on a lease-by-lease basis and bill or credit each tenant for any differences between the estimated expenses we billed and the actual expenses that were incurred. We recognize lease termination fees when there is a signed termination letter agreement, all of the conditions of the agreement have been met, and the tenant is no longer occupying the property. Rental income is reported net of amortization of inducements. The revenue recognition process is based on a five-step model to account for revenue arising from contracts with customers as outlined in ASC Topic 606 - Revenue from Contracts with Customers. We recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We have identified all of our revenue streams and we have concluded that rental income from leasing arrangements represents a substantial portion of our revenue and is governed and evaluated with the adoption of ASC Topic 842 - Lessors - Certain Leases with Variable Lease Payments (“Topic 842”). Investments in Real Estate Depreciation expense of buildings and improvements for the three months ended June 30, 2022 and 2021 was $62.3 million and $60.7 million, respectively. Depreciation expense of buildings and improvements for the six months ended June 30, 2022 and 2021 was $124.6 million and $121.9 million, respectively. Leases As a lessor, we lease space in our MOBs primarily to medical enterprises for terms generally ranging from three Leases, for which we are the lessee, are classified as separate components on our accompanying condensed consolidated balance sheets. Operating leases are included as right-of-use (“ROU”) assets - operating leases, net, with a corresponding lease liability. Financing lease assets are included in receivables and other assets, net, with a corresponding lease liability in security deposits, prepaid rent and other liabilities. A lease liability is recognized for our obligation related to the lease and an ROU asset represents our right to use the underlying asset over the lease term. Refer to Note 7 - Leases in the accompanying notes to the condensed consolidated financial statements for more detail relating to our leases. Real Estate Held for Sale We consider properties held for sale once management commits to a plan to sell the property and has determined that the sale is probable and expected to occur within one year. Upon classification as held for sale, we record the property at the lower of its carrying amount or fair value, less costs to sell, and cease depreciation and amortization. The fair value is generally based on a discounted cash flow analysis, which involves management's best estimate of market participants' holding periods, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements. As of June 30, 2022, the Company had no properties classified as held for sale. As of December 31, 2021, the Company had one property classified as held for sale. Real Estate Notes Receivable Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner and/or corporate guarantees . Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses. As of June 30, 2022, real estate notes receivable, net totaled $75.9 million. During the six months ended June 30, 2022, we recognized interest income of $3.2 million related to real estate notes receivable. The following table summarizes real estate notes receivable as of June 30, 2022 (in thousands): Stated Interest Rate Maximum Loan Commitment Outstanding Loan Amount Origination Date Maturity Date June 30, 2022 Mezzanine Loans - Texas (1) 6/24/2021 6/24/2024 8 % $ 54,119 $ 53,756 Mezzanine Loan - North Carolina 12/22/2021 12/22/2024 8 % 6,000 6,000 Mortgage Loan - Texas 6/30/2021 7/1/2022 10 % 15,000 15,000 Construction Loan - Florida 5/17/2022 2/27/2026 6 % 65,000 1,464 76,220 Accrued interest receivable 311 Unamortized fees and costs (659) Unearned revenue — $ 75,872 (1) Interest on these mezzanine loans is accrued and funded utilizing interest reserves, which is included in the maximum loan commitment, and such accrued interest is added to the note receivable balance. Pursuant to ASC Topic 326 - Financial Instruments - Credit Losses ( “Topic 326”) , we adopted a policy to evaluate current expected credit losses at the inception of loans qualifying for treatment under Topic 326. We utilize a probability of default method approach for estimating current expected credit losses and have determined that the current risk of credit loss is remote. Accordingly, we have recorded no reserve for credit loss as of June 30, 2022. Unconsolidated Joint Ventures We account for our investments in unconsolidated joint ventures using the equity method of accounting because we have the ability to exercise significant influence, but not control, over the financial and operational policy decisions of the investments. Using the equity method of accounting, the initial investment is recognized at cost and subsequently adjusted for our share of the net income and any distributions from the joint venture. As of June 30, 2022 and December 31, 2021, we had a 50% interest in one such investment with a carrying value and maximum exposure to risk of $62.1 million and $62.8 million, respectively, which is recorded in investment in unconsolidated joint venture on the accompanying condensed consolidated balance sheets. We record our share of net income in income from unconsolidated joint venture on the accompanying condensed consolidated statements of operations. For each of the three months ended June 30, 2022 and 2021, we recognized income of $0.4 million. For each of the six months ended June 30, 2022 and 2021, we recognized income of $0.8 million. Recently Issued or Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU 2021-05, Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments In July 2021, the FASB issued ASU 2021-05, which amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. The update is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. We adopted ASU 2021-05 effective as of January 1, 2022. The adoption of this standard did not have a material impact on our financial statements. Recently Issued Accounting Pronouncements ASU 2021-01, Reference Rate Reform (Topic 848) In January 2021, the FASB issued ASU 2021-01, which amends the scope of ASU 2020-04. The amendments of ASU 2021-01 clarify that certain optional expedients and exceptions to Topic 848 for contract modification and hedge accounting apply to derivatives that are affected by the discounting transition. For information related to the Company's current cash flow hedges, refer to Note 9 - Derivative Financial Instruments and Hedging Activities. The amendments are elective and effective immediately for contract modifications made through December 31, 2022. We do not expect that this ASU will have a material impact on our financial statements. |
Investments in Real Estate
Investments in Real Estate | 6 Months Ended |
Jun. 30, 2022 | |
Investments [Abstract] | |
Investments in Real Estate | Investments in Real Estate For the six months ended June 30, 2022, our investments had an aggregate purchase price of $25.7 million. As part of these investments, we incurred approximately $0.2 million of capitalized costs. The allocations for these investments, in which we own a controlling financial interest, are set forth below in the aggregate for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Land $ 3,812 $ 1,093 Building and improvements 19,761 45,629 In place leases 2,121 5,291 Below market leases (28) (79) Above market leases — 66 ROU assets — (1,372) Net real estate assets acquired 25,666 50,628 Other, net — 2,397 Aggregate purchase price $ 25,666 $ 53,025 The acquired intangible assets and liabilities referenced above had weighted average lives of the following terms for the six months ended June 30, 2022 and 2021, respectively (in years): Six Months Ended June 30, 2022 2021 Acquired intangible assets 4.2 4.2 Acquired intangible liabilities 4.1 5.7 |
Dispositions and Impairment
Dispositions and Impairment | 6 Months Ended |
Jun. 30, 2022 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Dispositions and Impairment | Dispositions and Impairment Dispositions During the six months ended June 30, 2022, we closed the sale of a tenant purchase option on one of our MOBs located in Georgia for a gross sales price of $26.8 million, resulting in a net loss to us of approximately four thousand dollars. During the six months ended June 30, 2021, we sold a 13 property portfolio with locations in Tennessee and Virginia for a gross sales price of $67.5 million, resulting in a net gain to us of approximately $32.8 million. Impairment During the three and six months ended June 30, 2022, we recorded no impairment charges. During the three and six months ended June 30, 2021, we recorded impairment charges of $16.8 million on two properties, for which the holding period was revised by the Company to be less than the previously estimated useful life. The estimated fair values were based on a purchase option and a pending sales agreement, both of which were executed subsequent to June 30, 2021. |
Intangible Assets and Liabiliti
Intangible Assets and Liabilities | 6 Months Ended |
Jun. 30, 2022 | |
Identified Intangibles, Net [Abstract] | |
Intangible Assets and Liabilities | Intangible Assets and Liabilities Intangible assets and liabilities consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands, except with respect to the weighted average remaining amortization terms): June 30, 2022 December 31, 2021 Balance Weighted Average Remaining Balance Weighted Average Remaining Assets: In place leases $ 334,807 9.3 $ 349,863 9.3 Tenant relationships 47,931 10.9 54,851 10.8 Above market leases 20,548 6.8 21,537 6.9 403,286 426,251 Accumulated amortization (210,279) (213,801) Total $ 193,007 9.3 $ 212,450 9.3 Liabilities: Below market leases $ 53,695 14.6 $ 55,073 14.3 Accumulated amortization (25,024) (23,742) Total $ 28,671 14.6 $ 31,331 14.3 The following is a summary of the net intangible amortization for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization recorded against rental income related to above and (below) market leases $ (634) $ (641) $ (1,283) $ (1,233) Amortization expense related to in place leases and tenant relationships 9,843 11,340 20,159 23,227 |
Receivables and Other Assets
Receivables and Other Assets | 6 Months Ended |
Jun. 30, 2022 | |
Receivables and Other Assets [Abstract] | |
Receivables and Other Assets | Receivables and Other Assets Receivables and other assets consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Tenant receivables, net $ 10,131 $ 10,477 Other receivables, net 10,335 6,098 Deferred financing costs, net 7,697 7,055 Deferred leasing costs, net 48,418 45,008 Straight-line rent receivables, net 149,602 142,604 Prepaid expenses, deposits, equipment and other, net 34,549 38,301 Derivative financial instruments - interest rate swaps 7,721 — Real estate notes receivable, net 75,872 69,114 Finance ROU asset, net 16,108 16,284 Total $ 360,433 $ 334,941 The following is a summary of the amortization of deferred leasing costs and financing costs for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization expense related to deferred leasing costs $ 2,296 $ 2,204 $ 4,523 $ 4,427 Interest expense related to deferred financing costs 1,560 431 2,913 862 |
Leases
Leases | 6 Months Ended |
Jun. 30, 2022 | |
Leases [Abstract] | |
Leases | Leases For the three and six months ended June 30, 2022, we added one new ground lease that commenced in June 2022. Based on our analysis, we concluded that its classification was an operating lease. Lessee - Maturity of Lease Liabilities The following table summarizes the future minimum lease obligations of our operating and finance leases as of June 30, 2022 (in thousands): Year Operating Leases Finance Leases 2022 $ 5,378 $ 316 2023 10,884 635 2024 10,411 640 2025 9,899 645 2026 9,901 656 2027 9,886 668 Thereafter 591,325 36,856 Total undiscounted lease payments $ 647,684 $ 40,416 Less: Interest (450,693) (23,506) Present value of lease liabilities $ 196,991 $ 16,910 Lessor - Lease Revenues and Maturity of Future Minimum Rents For the three months ended June 30, 2022 and 2021, we recognized $198.0 million and $187.4 million, respectively, of rental and other lease-related income related to our operating leases, of which $47.4 million and $42.2 million, respectively, were variable lease payments. For the six months ended June 30, 2022 and 2021, we recognized $397.3 million and $377.8 million, respectively, of rental and other lease-related income related to our operating leases, of which $95.5 million and $87.3 million, respectively, were variable lease payments. The following table summarizes the future minimum rent contractually due under operating leases, excluding tenant reimbursements of certain costs, as of June 30, 2022 (in thousands): Year Amount 2022 $ 290,284 2023 551,493 2024 495,354 2025 436,400 2026 388,471 2027 318,837 Thereafter 1,345,024 Total $ 3,825,863 |
Debt
Debt | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Debt | Debt Debt consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Unsecured revolving credit facility $ 65,000 $ — Unsecured term loans 500,000 500,000 Unsecured senior notes 2,550,000 2,550,000 Fixed rate mortgages — — $ 3,115,000 $ 3,050,000 Deferred financing costs, net (16,426) (17,975) Discount, net (3,931) (3,903) Total $ 3,094,643 $ 3,028,122 Unsecured Credit Agreement Unsecured Revolving Credit Facility due 2025 On October 6, 2021, we entered into a third amended and restated revolving credit and term loan agreement (the “Credit Agreement”), which includes an unsecured revolving credit facility in an aggregate maximum principal amount of $1.0 billion (the “Revolver”) and a term loan facility in an aggregate maximum principal amount of $300.0 million (the “Term Loan”). The Credit Agreement extended the maturities of the unsecured revolving credit facility and the unsecured term loan to October 31, 2025. The maximum principal amount of the Unsecured Credit Agreement may be increased by up to $750.0 million, subject to certain conditions, for a total principal amount of $2.05 billion. Borrowings under the Revolver bear interest at a per annum rate equal to LIBOR plus a margin ranging from 0.725% to 1.40% based on our credit rating. We are also required to pay a facility fee on the aggregate commitments under the Revolver at a per annum rate ranging from 0.125% to 0.30% based on our credit rating. We incurred financing costs of $6.2 million in relation to the credit facility, which are being amortized through the maturity date. As of June 30, 2022, we had $65.0 million outstanding under this unsecured revolving credit facility. The margin associated with our borrowings was 0.85% per annum and the facility fee was 0.20% per annum. All amounts outstanding under the Revolver were fully repaid on July 20, 2022 as part of the Merger. Unsecured Term Loan due 2025 Under the Unsecured Credit Agreement as noted above, we have a $300.0 million unsecured term loan, guaranteed by HTA, with a maturity date of October 31, 2025. Borrowings under this unsecured term loan bear interest at a per annum rate equal to LIBOR, plus a margin ranging from 0.80% to 1.60% per annum based on our credit rating. The margin associated with our borrowings as of June 30, 2022 was 0.95% per annum. We incurred financing costs of $1.8 million in relation to the unsecured term loan, which are being amortized through the maturity date. We have interest rate swaps hedging the floating interest rate, which resulted in a fixed rate of 2.37% per annum, based on our current credit rating. The current hedging arrangement matures on February 1, 2023. As of June 30, 2022, we had $300.0 million under this unsecured term loan outstanding. Unsecured Term Loan Agreement due 2023 On May 13, 2022, we entered into a new $1.125 billion term loan agreement (the “Term Loan Agreement”) which includes an unsecured term loan facility in an aggregate principal amount not to exceed $1.125 billion (the “Term Loan Facility”). The Term Loan Facility is scheduled to mature on May 13, 2023. We have the right to extend the maturity date to May 13, 2024, pursuant to the Term Loan Agreement. Borrowings under the Term Loan Facility will bear interest at either the “Base Rate” or the “Adjusted Term SOFR Rate” upon our request as follows; (i) The Base Rate is equal to the greatest of the prime rate plus 1/2 of 1%, and a rate based on the Federal Reserve Bank of New York’s secured overnight term loan financing rate plus 1%, plus in any case a margin ranging from 0.00% to 0.600% per annum based on our credit rating or (ii) The “Adjusted Term SOFR Rate” is equal to a rate based on the Federal Reserve Bank of New York’s secured overnight term loan financing rate plus 0.10%, plus a margin ranging from 0.800% to 1.600% per annum based on our credit rating. We incurred financing costs of $1.8 million in relation to the Term Loan Facility, which are being amortized through the maturity date. On July 14, 2022, the full amount of the Term Loan Facility to fund the Special Distribution Payment pursuant to the terms of the Merger Agreement with HR was drawn. $200.0 Million Unsecured Term Loan due 2024 In 2018, HTALP entered into a modification of our $200.0 million unsecured term loan previously due in 2023. The modification decreased pricing at our current credit rating by 65 basis points and extended the maturity date to January 15, 2024. The other material terms of the unsecured term loan prior to the modification remained substantially unchanged. Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 0.75% to 1.65% per annum based on our credit rating. The margin associated with our borrowings as of June 30, 2022 was 1.00% per annum. HTALP had interest rate swaps on the balance, which resulted in a fixed interest rate at 2.32% per annum. As of June 30, 2022, we had $200.0 million under this unsecured term loan outstanding. $600.0 Million Unsecured Senior Notes due 2026 In September 2019, in connection with the $650.0 million unsecured senior notes due 2030 referenced below, HTALP issued $250.0 million as additional unsecured senior notes to the $350.0 million aggregate principal of senior notes issued on July 12, 2016, all of which are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 3.50% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 103.66% and 99.72%, respectively, of the principal amount thereof, with an effective yield to maturity of 2.89% and 3.53% per annum, respectively. As of June 30, 2022, we had $600.0 million of these unsecured senior notes outstanding that mature on August 1, 2026. $500.0 Million Unsecured Senior Notes due 2027 In 2017, HTALP issued $500.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 3.75% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 99.49% of the principal amount thereof, with an effective yield to maturity of 3.81% per annum. As of June 30, 2022, we had $500.0 million of these unsecured senior notes outstanding that mature on July 1, 2027. $650.0 million Unsecured Senior Notes due 2030 In September 2019, in connection with the $250.0 million additional unsecured senior notes due 2026 referenced above, HTALP issued $650.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 3.10% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 99.66% of the principal amount thereof, with an effective yield to maturity of 3.14% per annum. Proceeds from the issuance of $900.0 million of these notes were used, in part, to redeem a total of $700.0 million of unsecured senior notes. As of June 30, 2022, HTALP had $650.0 million of these unsecured senior notes outstanding that mature on February 15, 2030. $800.0 million Unsecured Senior Notes due 2031 In September 2020, HTALP issued $800.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 2.00% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 99.20% of the principal amount thereof, with an effective yield to maturity of 2.09% per annum. We incurred financing costs of $6.8 million in relation to this transaction, which are being amortized through the maturity date. Proceeds from the issuance of these unsecured notes were used, in part, to redeem $300.0 million of unsecured senior notes. As of June 30, 2022, we had $800.0 million of these unsecured senior notes outstanding that mature on March 15, 2031. Future Debt Maturities The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of June 30, 2022 (in thousands): Year Amount 2022 $ — 2023 — 2024 200,000 2025 365,000 2026 600,000 Thereafter 1,950,000 Total $ 3,115,000 Deferred Financing Costs In February 2022, as part of the $1.7 billion bridge financing commitment secured in connection with the Merger, we incurred commitment fees of approximately $5.4 million. In May 2022, this financing commitment was replaced with a $1.125 billion unsecured Term Loan Facility (see above for more details of this transaction) with the remaining unamortized commitment fees written off, causing a loss on extinguishment of debt of $3.6 million. With the new Term Loan Facility we incurred approximately $1.8 million in financing costs, which will be amortized through the expiration date of May 13, 2023. As of June 30, 2022, the future amortization of our deferred financing costs is as follows (in thousands): Year Amount 2022 $ 1,554 2023 3,107 2024 2,725 2025 2,604 2026 1,839 Thereafter 4,597 Total $ 16,426 Debt Covenants |
Derivative Financial Instrument
Derivative Financial Instruments and Hedging Activities | 6 Months Ended |
Jun. 30, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments and Hedging Activities | Derivative Financial Instruments and Hedging Activities Risk Management Objective of Using Derivative Financial Instruments We may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with our borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with our operating and financial structure as well as to hedge specific anticipated transactions. We do not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, we only enter into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which we and our affiliates may also have other financial relationships. We do not anticipate that any of the counterparties will fail to meet their obligations. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, the fair value of derivative financial instruments designated as cash flow hedges are adjusted to reflect the impact of our credit quality. Cash Flow Hedges of Interest Rate Risk Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish this objective, we primarily use interest rate swaps and treasury locks as part of our interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable rate amounts from a counterparty in exchange for us making fixed rate payments over the life of the agreements without an exchange of the underlying notional amount. A treasury lock is a synthetic forward sale of a U.S. treasury note, which is settled in cash based upon the difference between an agreed upon treasury rate and the prevailing treasury rate at settlement. Such treasury locks are entered into to effectively fix the treasury component of an upcoming debt issuance. Amounts reported in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets related to derivatives will be reclassified to interest expense as interest payments are made on our variable rate debt. During the next twelve months, we estimate that an additional $5.6 million will be reclassified from other comprehensive income in the accompanying condensed consolidated balance sheets as an increase to interest related to derivative financial instruments in the accompanying condensed consolidated statements of operations. As of June 30, 2022, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments): Interest Rate Swaps June 30, 2022 Number of instruments 7 Notional amount $ 500,000 The table below presents the fair value of our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, respectively (in thousands): Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives Designated as Hedging Instruments: Balance Sheet June 30, 2022 December 31, 2021 Balance Sheet June 30, 2022 December 31, 2021 Interest rate swaps Receivables and other assets $ 7,721 $ — Derivative financial instruments $ — $ 5,069 The table below presents the gain or loss recognized on our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, Effect of Derivative Instruments Location in Statement of Operations and Comprehensive Income (Loss) 2022 2021 2022 2021 Gain (loss) recognized in OCI Change in unrealized losses on cash flow hedges $ 3,255 $ (150) $ 10,473 $ 1,013 Gain (loss) reclassified from accumulated OCI into income Interest expense (830) (1,673) (2,429) (3,302) Credit Risk Related Contingent Features We have agreements with each of our derivative counterparties that contain a provision that if we default on any of our indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then we could also be declared in default on our derivative obligations. We also have agreements with each of our derivative counterparties that incorporate provisions from our indebtedness with a lender affiliate of the derivative counterparty requiring it to maintain certain minimum financial covenant ratios on our indebtedness. Failure to comply with the covenant provisions would result in us being in default on any derivative instrument obligations covered by these agreements. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Litigation Two purported stockholders of HTA filed actions in the United States District Court for the Southern District of New York captioned Stein v. Healthcare Trust of America, Inc. , Case No. No. 1:22cv-03703 (S.D.N.Y.), and Tiso v. Healthcare Trust of America, Inc. , Case No. 1:22CV03804 (S.D.N.Y.), alleging that the Registration Statement on Form S-4 filed by the Company with the SEC on May 2, 2022, which included the Preliminary Proxy Statement, was materially incomplete, false or misleading in certain respects, thereby allegedly violating Sections 14(a) and 20(a) of the Exchange Act (15 U.S.C. § § 78n(a), 78t(a)), and SEC Rule 14a-9 (17 C.F.R. § 240.14a-9) or 17 C.F.R. § 244.100 promulgated thereunder. In addition, a purported shareholder filed an action in the United States District Court for the Eastern District of New York, captioned Johnson v. Healthcare Trust of America, Inc. , Case No. 1:22-cv-03692 (E.D.N.Y.), which generally alleged that the Definitive Proxy Statement filed by HR on June 10, 2022 failed to disclose material information in connection with the Merger and that, as a result, the Definitive Proxy Statement is materially misleading in violation of Section 14(a) and Section 20(a) of the Exchange Act. These three actions collectively are referred to as the “Complaints”. Each of the Complaints had sought, among other things, to enjoin the Company and HR from consummating the Merger or, in the alternative, rescission of the Merger or damages. Although the Company believed that the claims asserted in the Complaints were without merit and that no supplemental disclosure was required under applicable law, in order to avoid the risk of the above actions delaying or adversely affecting the Merger, to alleviate the costs, risks and uncertainties inherent in litigation, to provide additional information to its stockholders, and without admitting any liability or wrongdoing, the Company voluntarily supplemented the Definitive Proxy Statement, and these Complaints have since been settled. Additional lawsuits may be filed against us, our Board of Directors, and/or other parties to the Merger in connection with the transactions contemplated by the Merger Agreement. In addition, we are, from time to time, also subject to claims and litigation arising in the ordinary course of business with respect to tenant litigation and threatened or asserted labor matters. We do not believe liability from any reasonably foreseeable disposition of the aforementioned claims and litigation, individually or in the aggregate, would have a material effect on our consolidated financial position, results of operations or cash flows. Environmental Matters We routinely monitor our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency. Other Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material adverse effect on our condensed consolidated financial position, results of operations or cash flows. |
Partners' Capital
Partners' Capital | 6 Months Ended |
Jun. 30, 2022 | |
Equity [Abstract] | |
Partners' Capital | Partners’ Capital HTALP’s operating partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner thereof determines. Dividend distributions are made such that a holder of one OP Unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of our common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of OP Units. Distributions Refer to our accompanying condensed statement of changes in partners’ capital for the distributions declared during the three and six months ended June 30, 2022 and 2021. As of June 30, 2022, declared, but unpaid, distributions totaling $75.8 million were included in accounts payable and accrued liabilities. On July 1, 2022, HTA’s Board of Directors announced a pro-rata quarterly dividend of $0.029 per share of common stock and per OP Unit to be paid on July 19, 2022 to stockholders and unitholders of record on July 14, 2022. On July 6, 2022, HTA’s Board of Directors announced a special distribution of $4.82 per share of common stock and per OP Unit pursuant to the Merger Agreement to be paid on July 27, 2022 to stockholders and unitholders of record on July 19, 2022. Incentive Plan HTA’s Incentive Plan permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by HTA’s Board of Directors. This Plan authorizes HTA to grant awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 10,000,000 shares. As of June 30, 2022, there were 9,647,839 awards available for grant under the Plan. Restricted Common Stock We recognized compensation expense, equal to the fair market value of HTA’s stock on the grant date, over the service period which is generally three As of June 30, 2022, we had $6.2 million of unrecognized compensation expense, net of estimated forfeitures, which we will recognize over a remaining weighted average period of 1.6 years. The following is a summary of our restricted common stock activity as of June 30, 2022 and 2021, respectively: June 30, 2022 June 30, 2021 Restricted Common Stock Weighted Restricted Common Stock Weighted Beginning balance 529,862 $ 28.83 436,399 $ 28.27 Granted 158,543 30.81 354,288 26.62 Vested (124,407) 27.37 (270,099) 27.48 Forfeited (7,690) 29.58 (6,767) 28.87 Ending balance 556,308 $ 29.71 513,821 $ 27.54 |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Financial Instruments Reported at Fair Value - Recurring The table below presents the carrying amounts and fair values of our financial instruments on a recurring basis as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Level 2 - Assets: Real estate notes receivable, net $ 75,872 $ 72,377 $ 69,114 $ 68,476 Derivative financial instruments 7,721 7,721 — — Level 2 - Liabilities: Derivative financial instruments $ — $ — $ 5,069 $ 5,069 Debt 3,094,643 2,797,099 3,028,122 3,117,602 The carrying amounts of cash and cash equivalents, tenant and other receivables, restricted cash, accounts payable, and accrued liabilities approximate fair value. There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our cash flow hedges fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our cash flow hedge positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our cash flow hedge valuations in their entirety are classified in Level 2 of the fair value hierarchy. For further discussion of the assumptions considered, refer to Note 2 - Summary of Significant Accounting Policies. Financial Instruments Reported at Fair Value - Non-Recurring We also have assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This category generally includes assets subject to impairment. We estimate fair value relating to impairment assessments based upon discounted cash flow and direct capitalization models that include all projected cash inflows and outflows over a specific holding period, or the contractual sales price, if applicable. Such projected cash flows are comprised of contractual rental revenues and forecasted rental revenues and expenses based on market conditions and expectations for growth. Capitalization rates and discount rates utilized in these models are based on a reasonable range of current market rates for each property analyzed. Based on these inputs, we determined that our valuation of properties using a discounted cash flow or a direct capitalization model were classified within Level 3 of the fair value hierarchy. For assets for which the estimated fair value was based on contractual sales prices, we determined that our valuation was classified within Level 2 of the fair value hierarchy. As of June 30, 2022 we had no assets subject to impairment. The table below presents our assets measured at fair value on a non-recurring basis as of June 30, 2022 and December 31, 2021 (in thousands): June 30, 2022 December 31, 2021 Fair Value Fair Value Level 2 - Assets: Real estate investment $ — $ 26,768 Level 3 - Assets: Real estate investments $ — $ 4,970 |
Per Unit Data
Per Unit Data | 6 Months Ended |
Jun. 30, 2022 | |
Earnings Per Share [Abstract] | |
Per Unit Data | Per Unit Data The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per unit data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests — — — — Net income attributable to common unitholders $ 14,422 $ 38,739 $ 33,088 $ 61,132 Denominator: Weighted average OP Units outstanding - basic 233,125 222,326 233,086 222,297 Dilutive units - OP Units convertible into common units — — — — Adjusted weighted average units outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common unit - basic: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28 Earnings per common unit - diluted: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28 |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 6 Months Ended |
Jun. 30, 2022 | |
Supplemental Cash Flow Elements [Abstract] | |
Supplemental Cash Flow Information | Supplemental Cash Flow Information The following is the supplemental cash flow information for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Supplemental Disclosure of Cash Flow Information: Interest paid, net of capitalized interest $ 50,284 $ 39,827 Cash paid for operating leases 7,609 7,942 Supplemental Disclosure of Noncash Investing and Financing Activities: Accrued capital expenditures $ 6,244 $ 13,065 Distributions declared, but not paid 75,765 71,302 ROU assets obtained in exchange for lease obligations 705 7,683 |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events On July 20, 2022, pursuant to that certain Agreement and Plan of Merger, dated as of February 28, 2022 (the “Merger Agreement”), by and among Healthcare Realty Trust Incorporated, a Maryland corporation (now known as HRTI, LLC, a Maryland limited liability company) (“Legacy HR”), Healthcare Trust of America, Inc., a Maryland corporation (now known as Healthcare Realty Trust Incorporated) (“Legacy HTA”), Healthcare Trust of America Holdings, LP, a Delaware limited partnership (now known as Healthcare Realty Holdings, L.P.) (the “OP”), and HR Acquisition 2, LLC, a Maryland limited liability company (“Merger Sub”). Pursuant to the Merger Agreement, on the Closing Date, Merger Sub merged with and into Legacy HR, with Legacy HR continuing as the surviving entity and a wholly-owned subsidiary of Legacy HTA (the “Merger”). Immediately following the Merger, Legacy HR converted to a Maryland limited liability company and changed its name to “HRTI, LLC” and Legacy HTA changed its name to “Healthcare Realty Trust Incorporated”. Legacy HR became a part of an umbrella partnership REIT (“UPREIT”) structure, which is intended to align the corporate structure of the combined company after giving effect to the Merger and the UPREIT reorganization (the “Combined Company”) and to provide a platform for the Combined Company to more efficiently acquire properties in a tax-deferred manner. The Combined Company operates under the name “Healthcare Realty Trust Incorporated” and its shares of class A common stock, $0.01 par value per share, trade on the New York Stock Exchange (the “NYSE”) under the ticker symbol “HR”. The following are subsequent events of the Combined Company, including those events related to the Merger which have relevance to the OP (and correspondingly, HTALP) pre-Merger. Executive Officers and Directors The executive officers of Legacy HR immediately preceding the Merger serve as the executive officers of the Combined Company. The board of directors of the Combined Company is comprised of all nine directors from Legacy HR’s board and four directors from Legacy HTA’s board. Exchange Offer In connection with the Merger, HTALP offered to exchange all validly tendered and accepted notes of each series previously issued by Legacy HR (the “Old HR Notes”) for (i) up to $250,000,000 of 3.875% Senior Notes due 2025 (the “2025 Notes”), (ii) up to $300,000,000 of 3.625% Senior Notes due 2028 (the “2028 Notes”), (iii) up to $300,000,000 of 2.400% Senior Notes due 2030 (the “2030 Notes”) and (iv) up to $300,000,000 of 2.050% Senior Notes due 2031 to be issued by the OP (the “2031 Notes” and, collectively, the “New HR Notes”) and solicited consents from holders of the Old HR Notes to amend the indenture governing the Old HR Notes to eliminate substantially all of the restrictive covenants in such indenture (the “Exchange Offers”). The New HR Notes were issued pursuant to an indenture dated July 22, 2022, among the OP, Legacy HTA and U.S. Bank Trust Company, National Association, as trustee, as supplemented by the first supplemental indenture, dated as of July 22, 2022, the second supplemental indenture, dated as of July 22, 2022, the third supplemental indenture, dated as of July 22, 2022 and the fourth supplemental indenture, dated as of July 22, 2022. Legacy HTA guaranteed the New HR Notes pursuant to (i) a guarantee of the 2025 Notes, (ii) a guarantee of the 2028 Notes, (iii) a guarantee of the 2030 Notes, and (iv) a guarantee of the 2031 Notes, each dated July 22, 2022. Legacy HTA and the OP filed a registration statement on Form S-4 (File No. 333-265593) relating to the issuance of the New HR Notes with the Securities and Exchange Commission (the “SEC”) on June 14, 2022, which was declared effective by the SEC on June 28, 2022. The following sets forth the results of the Exchange Offers: Series of Old HR Notes Tenders and Consents Received as of the Expiration Date Percentage of Total Outstanding Principal Amount of Such Series of Old HR Notes 3.875 % Senior Notes due 2025 $235,016,000 94.01 % 3.625 % Senior Notes due 2028 $290,246,000 96.75 % 2.400 % Senior Notes due 2030 $297,507,000 99.17 % 2.050 % Senior Notes due 2031 $298,858,000 99.62 % Credit Facilities In connection with the effectiveness of the Merger, Legacy HR (in a limited capacity), Legacy HTA and the OP entered into the Fourth Amended and Restated Credit and Term Loan Agreement (the “Credit Facility”) with Wells Fargo Bank, National Association, as Administrative Agent; Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., and Citibank, N.A., as Joint Book Runners; Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., U.S. Bank National Association, Citibank, N.A., The Bank of Nova Scotia, Capital One, National Association, U.S. Bank National Association, and PNC Capital Markets LLC, as Joint Lead Arrangers; and the other lenders named therein. The Credit Facility restructures the parties’ existing bank facilities and adds additional borrowing capacities for the Combined Company following the Merger. The OP is the borrower under the Credit Facility (in such capacity, the “Borrower”). • Legacy HR’s existing $200.0 million term loan facility and existing $150.0 million term loan facility under the Amended and Restated Term Loan Agreement, dated as of May 31, 2019 (as amended, restated, replaced, supplemented, or otherwise modified from time to time prior to July 20, 2022, the “Existing HR Term Loan Agreement”), by and among Legacy HR, the lenders party thereto from time to time and their assignees, as lenders, and the WF Administrative Agent, in each, case, were deemed continued and assumed by the Borrower under the Credit Facility, and the Existing HR Term Loan Agreement was terminated. ◦ The existing $200.0 million term loan facility was amended to: (a) conform to the terms of the Borrower’s other term loan facilities under the Credit Facility; (b) include two one-year extension options, resulting in a latest final maturity in May 2026; and (c) reprice to align with the pricing for the Borrower’s other term loan facilities under the Credit Facility; and ◦ The existing $150.0 million term loan facility was amended to conform to the terms of the Borrower’s other term loan facilities under the Credit Facility, and the existing maturity in June 2026 remains unchanged under the Credit Facility. • Legacy HTA’s and the OP’s existing $1.0 billion revolving credit facility was upsized to $1.5 billion (the “Revolver”) pursuant to the Credit Facility. The Revolver currently matures in October 2025, and the Credit Facility adds an additional one-year extension option for the Revolver, for a total of two one-year extension options. • Legacy HTA’s and the OP’s existing $300.0 million term loan facility was deemed continued pursuant to the Credit Facility and was amended to conform to the terms of the Borrower’s other term loan facilities under the Credit Facility. The existing maturity in October 2025 remains unchanged under the Credit Facility. • Legacy HTA’s and the OP’s existing $200.0 million term loan facility was deemed continued pursuant to the Credit Facility and was amended to (a) conform to the terms of the Borrower’s other term loan facilities under the Credit Facility; (b) extend the maturity from January 2024 to July 20, 2027; and (c) reprice to align with the pricing for the Borrower’s other term loan facilities under the Credit Facility. • The Credit Facility provides for a new $350.0 million delayed-draw term loan facility that is available to be drawn for 12 months after July 20, 2022 and has an initial maturity date of July 20, 2023, with two one-year extension options. The terms of any delayed draw term loans funded thereunder conform to the terms of the Borrower’s other term loan facilities under the Credit Facility, and the pricing for such delayed draw term loans aligns with the pricing for the Borrower’s other term loan facilities under the Credit Facility. • The Credit Facility provides for a new $300.0 million term loan facility that was funded on July 20, 2022 and has a maturity of January 20, 2028, with no extension options. The terms of such term loan facility conform to the terms of the Borrower’s other term loan facilities under the Credit Facility, and the pricing for such term loan facility aligns with the pricing for the Borrower’s other term loan facilities under the Credit Facility. Special Dividend On May 13, 2022, Legacy HTA entered into a new $1.125 billion term loan agreement to fund the special dividend pursuant to the terms of the Merger Agreement. Prior to the Merger, Legacy HTA drew against the term loan to fund the special dividend of $4.82 that was declared on July 6, 2022 for shareholders of record on July 19, 2022. The special dividend was paid to all Legacy HTA shareholders and OP Unitholders on July 27, 2022. We plan to repay the term loan with proceeds from asset sales and joint ventures. As of the date of this report, we have closed on $433 million in joint ventures and asset sales. The remainder is expected to close in the third quarter of 2022. Other Investment Activity |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements. |
Principles of Consolidation | Principles of Consolidation The condensed consolidated financial statements include the accounts of our subsidiaries and consolidated joint venture arrangements. The portions of the HTALP operating partnership’s subsidiaries not owned by us are presented as non-controlling interests on the accompanying condensed consolidated balance sheets and statements of operations, condensed consolidated statements of comprehensive income, and condensed consolidated statements of changes in partners’ capital. As of both June 30, 2022 and December 31, 2021, there were approximately 4.1 million of OP Units issued and outstanding held by parties other than our sole general partner, HTA. |
Use of Estimates | Use of Estimates The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that effect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent asset and liabilities. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in adverse ways, and those estimates could be different under different assumptions or conditions. |
Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of all highly liquid investments with a maturity of three months or less when purchased. Restricted cash is typically comprised of: (i) reserve accounts for property taxes, insurance, capital and tenant improvements; (ii) collateral accounts for debt and interest rate swaps; (iii) 1031 exchange funds; and (iv) deposits for future investments. |
Revenue Recognition | Revenue Recognition Minimum annual rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). Differences between rental income recognized and amounts contractually due under the lease agreements are recorded as straight-line rent receivables. Tenant reimbursements, which is comprised of additional amounts recoverable from tenants for real estate taxes, common area maintenance and other certain operating expenses are recognized as revenue on a gross basis in the period in which the related recoverable expenses are incurred. We accrue revenue corresponding to these expenses on a quarterly basis to adjust recorded amounts to our best estimate of the final annual amounts to be billed. Subsequent to year-end, on a calendar year basis, we perform reconciliations on a lease-by-lease basis and bill or credit each tenant for any differences between the estimated expenses we billed and the actual expenses that were incurred. We recognize lease termination fees when there is a signed termination letter agreement, all of the conditions of the agreement have been met, and the tenant is no longer occupying the property. Rental income is reported net of amortization of inducements. |
Leases | As a lessor, we lease space in our MOBs primarily to medical enterprises for terms generally ranging from three |
Leases | Leases, for which we are the lessee, are classified as separate components on our accompanying condensed consolidated balance sheets. Operating leases are included as right-of-use (“ROU”) assets - operating leases, net, with a corresponding lease liability. Financing lease assets are included in receivables and other assets, net, with a corresponding lease liability in security deposits, prepaid rent and other liabilities. A lease liability is recognized for our obligation related to the lease and an ROU asset represents our right to use the underlying asset over the lease term. Refer to Note 7 - Leases in the accompanying notes to the condensed consolidated financial statements for more detail relating to our leases. |
Real Estate Held for Sale | Real Estate Held for Sale We consider properties held for sale once management commits to a plan to sell the property and has determined that the sale is probable and expected to occur within one year. Upon classification as held for sale, we record the property at the lower of its carrying amount or fair value, less costs to sell, and cease depreciation and amortization. The fair value is generally based on a discounted cash flow analysis, which involves management's best estimate of market participants' holding periods, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements. |
Real Estate Notes Receivable | Real Estate Notes Receivable Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner and/or corporate guarantees . Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and |
Unconsolidated Joint Ventures | Unconsolidated Joint Ventures |
Recently Issued or Adopted Accounting Pronouncements | Recently Issued or Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU 2021-05, Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments In July 2021, the FASB issued ASU 2021-05, which amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. The update is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. We adopted ASU 2021-05 effective as of January 1, 2022. The adoption of this standard did not have a material impact on our financial statements. Recently Issued Accounting Pronouncements ASU 2021-01, Reference Rate Reform (Topic 848) In January 2021, the FASB issued ASU 2021-01, which amends the scope of ASU 2020-04. The amendments of ASU 2021-01 clarify that certain optional expedients and exceptions to Topic 848 for contract modification and hedge accounting apply to derivatives that are affected by the discounting transition. For information related to the Company's current cash flow hedges, refer to Note 9 - Derivative Financial Instruments and Hedging Activities. The amendments are elective and effective immediately for contract modifications made through December 31, 2022. We do not expect that this ASU will have a material impact on our financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Schedule of Cash and Cash Equivalents | The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets to the amounts shown on the accompanying condensed consolidated statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 29,714 $ 19,796 Restricted cash 4,559 70,542 Total cash, cash equivalents and restricted cash $ 34,273 $ 90,338 |
Schedule of Restricted Cash | The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets to the amounts shown on the accompanying condensed consolidated statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 29,714 $ 19,796 Restricted cash 4,559 70,542 Total cash, cash equivalents and restricted cash $ 34,273 $ 90,338 |
Schedule of Real Estate Held For Sale | The following table summarizes real estate notes receivable as of June 30, 2022 (in thousands): Stated Interest Rate Maximum Loan Commitment Outstanding Loan Amount Origination Date Maturity Date June 30, 2022 Mezzanine Loans - Texas (1) 6/24/2021 6/24/2024 8 % $ 54,119 $ 53,756 Mezzanine Loan - North Carolina 12/22/2021 12/22/2024 8 % 6,000 6,000 Mortgage Loan - Texas 6/30/2021 7/1/2022 10 % 15,000 15,000 Construction Loan - Florida 5/17/2022 2/27/2026 6 % 65,000 1,464 76,220 Accrued interest receivable 311 Unamortized fees and costs (659) Unearned revenue — $ 75,872 (1) Interest on these mezzanine loans is accrued and funded utilizing interest reserves, which is included in the maximum loan commitment, and such accrued interest is added to the note receivable balance. |
Investments in Real Estate (Tab
Investments in Real Estate (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Investments [Abstract] | |
Schedule of Purchase Price Allocation | The allocations for these investments, in which we own a controlling financial interest, are set forth below in the aggregate for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Land $ 3,812 $ 1,093 Building and improvements 19,761 45,629 In place leases 2,121 5,291 Below market leases (28) (79) Above market leases — 66 ROU assets — (1,372) Net real estate assets acquired 25,666 50,628 Other, net — 2,397 Aggregate purchase price $ 25,666 $ 53,025 |
Schedule of Weighted Average Lives of Acquired Intangible Assets and Liabilities | The acquired intangible assets and liabilities referenced above had weighted average lives of the following terms for the six months ended June 30, 2022 and 2021, respectively (in years): Six Months Ended June 30, 2022 2021 Acquired intangible assets 4.2 4.2 Acquired intangible liabilities 4.1 5.7 |
Intangible Assets and Liabili_2
Intangible Assets and Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Identified Intangibles, Net [Abstract] | |
Schedule of Intangible Assets and Liabilities | Intangible assets and liabilities consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands, except with respect to the weighted average remaining amortization terms): June 30, 2022 December 31, 2021 Balance Weighted Average Remaining Balance Weighted Average Remaining Assets: In place leases $ 334,807 9.3 $ 349,863 9.3 Tenant relationships 47,931 10.9 54,851 10.8 Above market leases 20,548 6.8 21,537 6.9 403,286 426,251 Accumulated amortization (210,279) (213,801) Total $ 193,007 9.3 $ 212,450 9.3 Liabilities: Below market leases $ 53,695 14.6 $ 55,073 14.3 Accumulated amortization (25,024) (23,742) Total $ 28,671 14.6 $ 31,331 14.3 |
Summary of Net Intangible Amortization | The following is a summary of the net intangible amortization for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization recorded against rental income related to above and (below) market leases $ (634) $ (641) $ (1,283) $ (1,233) Amortization expense related to in place leases and tenant relationships 9,843 11,340 20,159 23,227 |
Receivables and Other Assets (T
Receivables and Other Assets (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Receivables and Other Assets [Abstract] | |
Schedule of Receivables and Other Assets | Receivables and other assets consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Tenant receivables, net $ 10,131 $ 10,477 Other receivables, net 10,335 6,098 Deferred financing costs, net 7,697 7,055 Deferred leasing costs, net 48,418 45,008 Straight-line rent receivables, net 149,602 142,604 Prepaid expenses, deposits, equipment and other, net 34,549 38,301 Derivative financial instruments - interest rate swaps 7,721 — Real estate notes receivable, net 75,872 69,114 Finance ROU asset, net 16,108 16,284 Total $ 360,433 $ 334,941 |
Summary of Amortization of Deferred Leasing Costs and Deferred Financing Costs | The following is a summary of the amortization of deferred leasing costs and financing costs for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization expense related to deferred leasing costs $ 2,296 $ 2,204 $ 4,523 $ 4,427 Interest expense related to deferred financing costs 1,560 431 2,913 862 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Leases [Abstract] | |
Summary of lease repayments of operating lease liabilities | The following table summarizes the future minimum lease obligations of our operating and finance leases as of June 30, 2022 (in thousands): Year Operating Leases Finance Leases 2022 $ 5,378 $ 316 2023 10,884 635 2024 10,411 640 2025 9,899 645 2026 9,901 656 2027 9,886 668 Thereafter 591,325 36,856 Total undiscounted lease payments $ 647,684 $ 40,416 Less: Interest (450,693) (23,506) Present value of lease liabilities $ 196,991 $ 16,910 |
Schedule of undiscounted cash flows for future minimum rents | The following table summarizes the future minimum rent contractually due under operating leases, excluding tenant reimbursements of certain costs, as of June 30, 2022 (in thousands): Year Amount 2022 $ 290,284 2023 551,493 2024 495,354 2025 436,400 2026 388,471 2027 318,837 Thereafter 1,345,024 Total $ 3,825,863 |
Debt (Tables)
Debt (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | Debt consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Unsecured revolving credit facility $ 65,000 $ — Unsecured term loans 500,000 500,000 Unsecured senior notes 2,550,000 2,550,000 Fixed rate mortgages — — $ 3,115,000 $ 3,050,000 Deferred financing costs, net (16,426) (17,975) Discount, net (3,931) (3,903) Total $ 3,094,643 $ 3,028,122 |
Summary of Debt Maturities and Scheduled Principal Debt Repayments | The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of June 30, 2022 (in thousands): Year Amount 2022 $ — 2023 — 2024 200,000 2025 365,000 2026 600,000 Thereafter 1,950,000 Total $ 3,115,000 |
Schedule of Amortization of Deferred Financing Costs | As of June 30, 2022, the future amortization of our deferred financing costs is as follows (in thousands): Year Amount 2022 $ 1,554 2023 3,107 2024 2,725 2025 2,604 2026 1,839 Thereafter 4,597 Total $ 16,426 |
Derivative Financial Instrume_2
Derivative Financial Instruments and Hedging Activities (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Interest Rate Derivatives | As of June 30, 2022, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments): Interest Rate Swaps June 30, 2022 Number of instruments 7 Notional amount $ 500,000 The table below presents the fair value of our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, respectively (in thousands): Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives Designated as Hedging Instruments: Balance Sheet June 30, 2022 December 31, 2021 Balance Sheet June 30, 2022 December 31, 2021 Interest rate swaps Receivables and other assets $ 7,721 $ — Derivative financial instruments $ — $ 5,069 The table below presents the gain or loss recognized on our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, Effect of Derivative Instruments Location in Statement of Operations and Comprehensive Income (Loss) 2022 2021 2022 2021 Gain (loss) recognized in OCI Change in unrealized losses on cash flow hedges $ 3,255 $ (150) $ 10,473 $ 1,013 Gain (loss) reclassified from accumulated OCI into income Interest expense (830) (1,673) (2,429) (3,302) |
Partners' Capital (Tables)
Partners' Capital (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Equity [Abstract] | |
Schedule of Restricted Common Stock Activity | The following is a summary of our restricted common stock activity as of June 30, 2022 and 2021, respectively: June 30, 2022 June 30, 2021 Restricted Common Stock Weighted Restricted Common Stock Weighted Beginning balance 529,862 $ 28.83 436,399 $ 28.27 Granted 158,543 30.81 354,288 26.62 Vested (124,407) 27.37 (270,099) 27.48 Forfeited (7,690) 29.58 (6,767) 28.87 Ending balance 556,308 $ 29.71 513,821 $ 27.54 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The table below presents the carrying amounts and fair values of our financial instruments on a recurring basis as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Level 2 - Assets: Real estate notes receivable, net $ 75,872 $ 72,377 $ 69,114 $ 68,476 Derivative financial instruments 7,721 7,721 — — Level 2 - Liabilities: Derivative financial instruments $ — $ — $ 5,069 $ 5,069 Debt 3,094,643 2,797,099 3,028,122 3,117,602 |
Fair Value Measurements, Nonrecurring | The table below presents our assets measured at fair value on a non-recurring basis as of June 30, 2022 and December 31, 2021 (in thousands): June 30, 2022 December 31, 2021 Fair Value Fair Value Level 2 - Assets: Real estate investment $ — $ 26,768 Level 3 - Assets: Real estate investments $ — $ 4,970 |
Per Unit Data (Tables)
Per Unit Data (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Unit, Basic and Diluted | The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per unit data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests — — — — Net income attributable to common unitholders $ 14,422 $ 38,739 $ 33,088 $ 61,132 Denominator: Weighted average OP Units outstanding - basic 233,125 222,326 233,086 222,297 Dilutive units - OP Units convertible into common units — — — — Adjusted weighted average units outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common unit - basic: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28 Earnings per common unit - diluted: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28 |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Supplemental Cash Flow Information | The following is the supplemental cash flow information for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Supplemental Disclosure of Cash Flow Information: Interest paid, net of capitalized interest $ 50,284 $ 39,827 Cash paid for operating leases 7,609 7,942 Supplemental Disclosure of Noncash Investing and Financing Activities: Accrued capital expenditures $ 6,244 $ 13,065 Distributions declared, but not paid 75,765 71,302 ROU assets obtained in exchange for lease obligations 705 7,683 |
Subsequent Events (Tables)
Subsequent Events (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Subsequent Events [Abstract] | |
Results of the Exchange Offers | The following sets forth the results of the Exchange Offers: Series of Old HR Notes Tenders and Consents Received as of the Expiration Date Percentage of Total Outstanding Principal Amount of Such Series of Old HR Notes 3.875 % Senior Notes due 2025 $235,016,000 94.01 % 3.625 % Senior Notes due 2028 $290,246,000 96.75 % 2.400 % Senior Notes due 2030 $297,507,000 99.17 % 2.050 % Senior Notes due 2031 $298,858,000 99.62 % |
Organization and Description _2
Organization and Description of Business (Details) | Jul. 20, 2022 $ / shares shares | Jul. 19, 2022 $ / shares | Jun. 30, 2022 state |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Number of states in which the Company operates | state | 32 | ||
Business Acquisition [Line Items] | |||
Number of states in which the Company operates | state | 32 | ||
Subsequent Event | |||
Business Acquisition [Line Items] | |||
Common stock, par value (in dollars per share) | $ 0.01 | ||
Merger Agreement with Healthcare Realty Trust Incorporated | Subsequent Event | |||
Business Acquisition [Line Items] | |||
Common stock, par value (in dollars per share) | $ 0.01 | ||
Merger agreement conversion ratio (in shares) | shares | 1 | ||
Special distribution payment (in dollars per share) | $ 4.82 | ||
Healthcare Realty Trust Incorporated | Merger Agreement with Healthcare Realty Trust Incorporated | Subsequent Event | |||
Business Acquisition [Line Items] | |||
Common stock, par value (in dollars per share) | $ 0.01 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2022 USD ($) property shares | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) property shares | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) property shares | Dec. 31, 2020 USD ($) | |
Partners' Capital Notes [Abstract] | ||||||
Limited partner's capital, units issued (in shares) | shares | 4,050,493 | 4,050,493 | 4,142,408 | |||
Limited partner's capital, units outstanding (in shares) | shares | 4,050,493 | 4,050,493 | 4,142,408 | |||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] | ||||||
Cash and cash equivalents | $ 29,714 | $ 29,714 | $ 52,353 | |||
Restricted cash | 4,559 | 4,559 | 4,716 | |||
Total cash, cash equivalents and restricted cash | 34,273 | $ 90,338 | 34,273 | $ 90,338 | $ 57,069 | $ 118,765 |
Leases [Abstract] | ||||||
Interest income | $ 1,849 | 121 | 3,608 | 264 | ||
Expected credit losses | $ 0 | |||||
Unconsolidated Joint Ventures [Abstract] | ||||||
Investment in unconsolidated joint ventures, ownership percentage | 50% | 50% | 50% | |||
Investment in unconsolidated joint venture | $ 62,070 | $ 62,070 | $ 62,834 | |||
Income (loss) from unconsolidated joint venture | $ 401 | 406 | 801 | 798 | ||
Notes Receivable | ||||||
Leases [Abstract] | ||||||
Interest income | $ 3,200 | |||||
Disposal Group, Held-for-sale | ||||||
Leases [Abstract] | ||||||
Number of properties in portfolio | property | 0 | 0 | 1 | |||
Real estate notes receivable, net | $ 75,900 | $ 75,900 | ||||
Minimum | ||||||
Leases [Abstract] | ||||||
Lessor, term of contract | 3 years | 3 years | ||||
Maximum | ||||||
Leases [Abstract] | ||||||
Lessor, term of contract | 7 years | 7 years | ||||
Building and Building Improvements | ||||||
Real estate investments [Abstract] | ||||||
Depreciation expense | $ 62,300 | $ 60,700 | $ 124,600 | $ 121,900 | ||
Healthcare Trust of America Holdings, LP (HTALP) | ||||||
Partners' Capital Notes [Abstract] | ||||||
Limited partner's capital, units issued (in shares) | shares | 4,100,000 | 4,100,000 | 4,100,000 | |||
Limited partner's capital, units outstanding (in shares) | shares | 4,100,000 | 4,100,000 | 4,100,000 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details) | Jun. 30, 2022 USD ($) |
Mezzanine Loans and Mortgage Loan Texas | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |
Outstanding Loan Amount | $ 76,220,000 |
Accrued interest receivable | 311,000 |
Unamortized fees and costs | (659,000) |
Unearned revenue | 0 |
Real estate notes receivable, net | $ 75,872,000 |
Mezzanine Loans - Texas | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |
Stated Interest Rate | 8% |
Maximum Loan Commitment | $ 54,119,000 |
Outstanding Loan Amount | $ 53,756,000 |
Mezzanine Loan - North Carolina | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |
Stated Interest Rate | 8% |
Maximum Loan Commitment | $ 6,000,000 |
Outstanding Loan Amount | $ 6,000,000 |
Mortgage Loan - Texas | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |
Stated Interest Rate | 10% |
Maximum Loan Commitment | $ 15,000,000 |
Outstanding Loan Amount | $ 15,000,000 |
Construction Loan - Florida | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |
Stated Interest Rate | 6% |
Maximum Loan Commitment | $ 65,000,000 |
Outstanding Loan Amount | $ 1,464,000 |
Investments in Real Estate - Ac
Investments in Real Estate - Acquisitions (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Investments [Abstract] | ||
Aggregate purchase price | $ 25,666 | $ 53,025 |
Closing costs | $ 200 |
Investments in Real Estate - Pu
Investments in Real Estate - Purchase Price Allocation (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Jun. 30, 2021 |
Asset Acquisition | ||
Land | $ 3,812 | $ 1,093 |
Building and improvements | 19,761 | 45,629 |
In place leases | 2,121 | 5,291 |
Below market leases | (28) | (79) |
Above market leases | 0 | 66 |
ROU assets | 0 | (1,372) |
Net real estate assets acquired | 25,666 | 50,628 |
Other, net | 0 | 2,397 |
Aggregate purchase price | $ 25,666 | $ 53,025 |
Investments in Real Estate - We
Investments in Real Estate - Weighted Average Lives (Details) | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Investments [Abstract] | ||
Acquired intangible assets (in years) | 4 years 2 months 12 days | 4 years 2 months 12 days |
Acquired intangible liabilities (in years) | 4 years 1 month 6 days | 5 years 8 months 12 days |
Dispositions and Impairment (De
Dispositions and Impairment (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) property | Jun. 30, 2021 USD ($) derivative property | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Gain (loss) on sale of real estate, net | $ 0 | $ 32,753 | $ (4) | $ 32,753 |
Impairment | $ 0 | $ 16,825 | $ 0 | $ 16,825 |
Number of impaired assets | property | 2 | |||
GEORGIA | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Number of assets disposed | 1 | 13 | ||
Proceeds from the sale of real estate | $ 26,800 | $ 67,500 | ||
Gain (loss) on sale of real estate, net | $ (4,000) | $ 32,800 |
Intangible Assets and Liabili_3
Intangible Assets and Liabilities - Summary of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Assets: | ||
Gross | $ 403,286 | $ 426,251 |
Accumulated amortization | (210,279) | (213,801) |
Total | $ 193,007 | $ 212,450 |
Weighted Average Remaining Amortization in Years | 9 years 3 months 18 days | 9 years 3 months 18 days |
Liabilities: | ||
Accumulated amortization | $ (25,024) | $ (23,742) |
Total | $ 28,671 | $ 31,331 |
Weighted Average Remaining Amortization in Years | 14 years 7 months 6 days | 14 years 3 months 18 days |
Below market leases | ||
Liabilities: | ||
Gross | $ 53,695 | $ 55,073 |
Weighted Average Remaining Amortization in Years | 14 years 7 months 6 days | 14 years 3 months 18 days |
In place leases | ||
Assets: | ||
Gross | $ 334,807 | $ 349,863 |
Weighted Average Remaining Amortization in Years | 9 years 3 months 18 days | 9 years 3 months 18 days |
Tenant relationships | ||
Assets: | ||
Gross | $ 47,931 | $ 54,851 |
Weighted Average Remaining Amortization in Years | 10 years 10 months 24 days | 10 years 9 months 18 days |
Above market leases | ||
Assets: | ||
Gross | $ 20,548 | $ 21,537 |
Weighted Average Remaining Amortization in Years | 6 years 9 months 18 days | 6 years 10 months 24 days |
Intangible Assets and Liabili_4
Intangible Assets and Liabilities - Summary of Intangible Amortization (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Amortization recorded against rental income related to above and (below) market leases | ||||
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items] | ||||
Amortization of intangible assets and liabilities | $ (634) | $ (641) | $ (1,283) | $ (1,233) |
Amortization expense related to in place leases and tenant relationships | ||||
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items] | ||||
Amortization of intangible assets and liabilities | $ 9,843 | $ 11,340 | $ 20,159 | $ 23,227 |
Receivables and Other Assets -
Receivables and Other Assets - Schedule of Receivables and Other Assets (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Receivables and Other Assets [Abstract] | ||
Tenant receivables, net | $ 10,131 | $ 10,477 |
Other receivables, net | 10,335 | 6,098 |
Deferred financing costs, net | 7,697 | 7,055 |
Deferred leasing costs, net | 48,418 | 45,008 |
Straight-line rent receivables, net | 149,602 | 142,604 |
Prepaid expenses, deposits, equipment and other, net | 34,549 | 38,301 |
Derivative financial instruments - interest rate swaps | 7,721 | 0 |
Real estate notes receivable, net | 75,872 | 69,114 |
Finance ROU asset, net | 16,108 | 16,284 |
Total | $ 360,433 | $ 334,941 |
Receivables and Other Assets _2
Receivables and Other Assets - Amortization (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Receivables and Other Assets [Abstract] | ||||
Amortization expense related to deferred leasing costs | $ 2,296 | $ 2,204 | $ 4,523 | $ 4,427 |
Interest expense related to deferred financing costs | $ 1,560 | $ 431 | $ 2,913 | $ 862 |
Leases - Narrative (Details)
Leases - Narrative (Details) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 USD ($) lease | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) lease | Jun. 30, 2021 USD ($) | |
Leases [Abstract] | ||||
Number of new ground leases commenced | lease | 1 | 1 | ||
Rental and other revenues from operating lease payments | $ 198 | $ 187.4 | $ 397.3 | $ 377.8 |
Variable lease payments | $ 47.4 | $ 42.2 | $ 95.5 | $ 87.3 |
Leases - Maturity of Lease Liab
Leases - Maturity of Lease Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Operating Leases | ||
2022 | $ 5,378 | |
2023 | 10,884 | |
2024 | 10,411 | |
2025 | 9,899 | |
2026 | 9,901 | |
2027 | 9,886 | |
Thereafter | 591,325 | |
Total undiscounted lease payments | 647,684 | |
Less: Interest | (450,693) | |
Present value of lease liabilities | 196,991 | $ 196,286 |
Finance Leases | ||
2022 | 316 | |
2023 | 635 | |
2024 | 640 | |
2025 | 645 | |
2026 | 656 | |
2027 | 668 | |
Thereafter | 36,856 | |
Total undiscounted lease payments | 40,416 | |
Less: Interest | (23,506) | |
Present value of lease liabilities | $ 16,910 |
Leases - Lease Revenues and Mat
Leases - Lease Revenues and Maturity of Future Minimum Rents (Details) $ in Thousands | Jun. 30, 2022 USD ($) |
Leases [Abstract] | |
2022 | $ 290,284 |
2023 | 551,493 |
2024 | 495,354 |
2025 | 436,400 |
2026 | 388,471 |
2027 | 318,837 |
Thereafter | 1,345,024 |
Total | $ 3,825,863 |
Debt - Schedule of Debt (Detail
Debt - Schedule of Debt (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Debt Instrument | ||
Total debt, gross | $ 3,115,000 | $ 3,050,000 |
Deferred financing costs, net | (16,426) | (17,975) |
Discount, net | (3,931) | (3,903) |
Total | 3,094,643 | 3,028,122 |
Unsecured term loans | ||
Debt Instrument | ||
Total debt, gross | 500,000 | 500,000 |
Unsecured senior notes | ||
Debt Instrument | ||
Total debt, gross | 2,550,000 | 2,550,000 |
Fixed rate mortgages | ||
Debt Instrument | ||
Total debt, gross | 0 | 0 |
Unsecured revolving credit facility | ||
Debt Instrument | ||
Unsecured revolving credit facility | $ 65,000 | $ 0 |
Debt - Narrative (Details)
Debt - Narrative (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||
Feb. 28, 2022 | Oct. 06, 2021 | May 31, 2022 | Sep. 30, 2020 | Sep. 30, 2019 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2018 | May 13, 2022 | Dec. 31, 2021 | Dec. 31, 2017 | Jul. 12, 2016 | |
Debt Instrument | ||||||||||||||
Outstanding amount | $ 3,115,000,000 | $ 3,115,000,000 | $ 3,050,000,000 | |||||||||||
Loss on extinguishment of debt, net | $ 3,600,000 | 3,615,000 | $ 0 | 3,615,000 | $ 0 | |||||||||
Deferred financing costs | 7,154,000 | $ 0 | ||||||||||||
Term Loan Agreement | ||||||||||||||
Debt Instrument | ||||||||||||||
Outstanding amount | 1,125,000,000 | $ 1,125,000,000 | ||||||||||||
Term Loan Facility | ||||||||||||||
Debt Instrument | ||||||||||||||
Debt financing cost | $ 1,800,000 | 1,800,000 | ||||||||||||
Unsecured term loans | ||||||||||||||
Debt Instrument | ||||||||||||||
Line of credit facility, borrowing capacity | $ 300,000,000 | |||||||||||||
Outstanding amount | 500,000,000 | $ 500,000,000 | 500,000,000 | |||||||||||
Unsecured term loans | Base Rate | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.50% | |||||||||||||
Unsecured term loans | Fed Funds Effective Rate Overnight Index Swap Rate | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 1% | |||||||||||||
Unsecured term loans | SOFR | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.10% | |||||||||||||
Unsecured term loans | $300.0 Million Unsecured Term Loan due 2023 | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.95% | |||||||||||||
Debt issuance costs | 1,800,000 | $ 1,800,000 | ||||||||||||
Outstanding amount | $ 300,000,000 | $ 300,000,000 | ||||||||||||
Weighted average interest rate with interest rate swap impact | 2.37% | 2.37% | ||||||||||||
Unsecured term loans | $300.0 Million Unsecured Term Loan due 2023 | LIBOR | Minimum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.80% | |||||||||||||
Unsecured term loans | $300.0 Million Unsecured Term Loan due 2023 | LIBOR | Maximum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 1.60% | |||||||||||||
Unsecured term loans | $200.0 Million Unsecured Term Loan due 2024 | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 1% | 65% | ||||||||||||
Outstanding amount | $ 200,000,000 | $ 200,000,000 | ||||||||||||
Weighted average interest rate with interest rate swap impact | 2.32% | 2.32% | ||||||||||||
Debt instrument, face amount | $ 200,000,000 | $ 200,000,000 | $ 200,000,000 | |||||||||||
Unsecured term loans | $200.0 Million Unsecured Term Loan due 2024 | LIBOR | Minimum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.75% | |||||||||||||
Unsecured term loans | $200.0 Million Unsecured Term Loan due 2024 | LIBOR | Maximum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 1.65% | |||||||||||||
Unsecured term loans | Term Loan Facility | ||||||||||||||
Debt Instrument | ||||||||||||||
Line of credit facility, borrowing capacity | $ 1,125,000,000 | |||||||||||||
Unsecured senior notes | ||||||||||||||
Debt Instrument | ||||||||||||||
Outstanding amount | 2,550,000,000 | $ 2,550,000,000 | 2,550,000,000 | |||||||||||
Extinguishment of debt | 700,000,000 | |||||||||||||
Unsecured senior notes | $600.0 Million Unsecured Senior Notes due 2026 | ||||||||||||||
Debt Instrument | ||||||||||||||
Outstanding amount | 600,000,000 | 600,000,000 | ||||||||||||
Debt instrument, face amount | 600,000,000 | 600,000,000 | ||||||||||||
Debt instrument, stated interest rate | 3.50% | |||||||||||||
Unsecured senior notes | $650.0 Million Unsecured Senior Notes | ||||||||||||||
Debt Instrument | ||||||||||||||
Debt instrument, face amount | $ 650,000,000 | 650,000,000 | 650,000,000 | |||||||||||
Debt instrument, stated interest rate | 3.10% | |||||||||||||
Debt instrument, percentage of principal amount received | 99.66% | |||||||||||||
Debt instrument, effective interest rate | 3.14% | |||||||||||||
Proceeds from issuance of debt | 900,000,000 | |||||||||||||
Unsecured senior notes | $250.0 Million Unsecured Senior Notes | ||||||||||||||
Debt Instrument | ||||||||||||||
Proceeds from unsecured senior notes | $ 250,000,000 | |||||||||||||
Debt instrument, percentage of principal amount received | 99.72% | |||||||||||||
Debt instrument, effective interest rate | 3.53% | |||||||||||||
Unsecured senior notes | $350.0 Million Unsecured Senior Notes | ||||||||||||||
Debt Instrument | ||||||||||||||
Debt instrument, face amount | $ 350,000,000 | |||||||||||||
Debt instrument, percentage of principal amount received | 103.66% | |||||||||||||
Debt instrument, effective interest rate | 2.89% | |||||||||||||
Unsecured senior notes | $500.0 Million Unsecured Senior Notes due 2027 | ||||||||||||||
Debt Instrument | ||||||||||||||
Outstanding amount | 500,000,000 | 500,000,000 | ||||||||||||
Debt instrument, face amount | 500,000,000 | 500,000,000 | $ 500,000,000 | |||||||||||
Debt instrument, stated interest rate | 3.75% | |||||||||||||
Debt instrument, percentage of principal amount received | 99.49% | |||||||||||||
Debt instrument, effective interest rate | 3.81% | |||||||||||||
Unsecured senior notes | $800.0 Million Unsecured Senior Notes due 2031 | ||||||||||||||
Debt Instrument | ||||||||||||||
Debt instrument, face amount | 800,000,000 | 800,000,000 | ||||||||||||
Proceeds from unsecured senior notes | $ 800,000,000 | |||||||||||||
Debt instrument, stated interest rate | 2% | |||||||||||||
Debt instrument, percentage of principal amount received | 99.20% | |||||||||||||
Debt instrument, effective interest rate | 2.09% | |||||||||||||
Extinguishment of debt | $ 300,000,000 | |||||||||||||
Deferred financing costs | $ 6,800,000 | |||||||||||||
Unsecured revolving credit facility | ||||||||||||||
Debt Instrument | ||||||||||||||
Conditional maximum borrowing capacity | 2,050,000,000 | 2,050,000,000 | ||||||||||||
Maximum borrowing capacity, conditional increase | 750,000,000 | $ 750,000,000 | ||||||||||||
Basis spread on variable rate | 0.85% | |||||||||||||
Line of credit facility, commitment fee | 0.20% | |||||||||||||
Debt issuance costs | 6,200,000 | $ 6,200,000 | ||||||||||||
Unsecured revolving credit facility | $ 65,000,000 | $ 65,000,000 | $ 0 | |||||||||||
Unsecured revolving credit facility | Line of Credit | ||||||||||||||
Debt Instrument | ||||||||||||||
Line of credit facility, borrowing capacity | $ 1,000,000,000 | |||||||||||||
Unsecured revolving credit facility | Line of Credit | Minimum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.80% | |||||||||||||
Line of credit facility, commitment fee | 0.125% | |||||||||||||
Unsecured revolving credit facility | Line of Credit | Maximum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 1.60% | |||||||||||||
Line of credit facility, commitment fee | 0.30% | |||||||||||||
Unsecured revolving credit facility | Line of Credit | LIBOR | Minimum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.725% | |||||||||||||
Unsecured revolving credit facility | Line of Credit | LIBOR | Maximum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 1.40% | |||||||||||||
Unsecured revolving credit facility | Line of Credit | Fed Funds Effective Rate Overnight Index Swap Rate | Minimum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0% | |||||||||||||
Unsecured revolving credit facility | Line of Credit | Fed Funds Effective Rate Overnight Index Swap Rate | Maximum | ||||||||||||||
Debt Instrument | ||||||||||||||
Basis spread on variable rate | 0.60% | |||||||||||||
Bridge Financing Facility | Line of Credit | Merger Agreement with Healthcare Realty Trust Incorporated | ||||||||||||||
Debt Instrument | ||||||||||||||
Line of credit facility, borrowing capacity | $ 1,700,000,000 | |||||||||||||
Commitment fees | $ 5,400,000 |
Debt - Principal Maturity Sched
Debt - Principal Maturity Schedule (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Debt Disclosure [Abstract] | ||
2022 | $ 0 | |
2023 | 0 | |
2024 | 200,000 | |
2025 | 365,000 | |
2026 | 600,000 | |
Thereafter | 1,950,000 | |
Total | $ 3,115,000 | $ 3,050,000 |
Debt - Amortization of Deferred
Debt - Amortization of Deferred Financing Costs (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Debt Disclosure [Abstract] | ||
2022 | $ 1,554 | |
2023 | 3,107 | |
2024 | 2,725 | |
2025 | 2,604 | |
2026 | 1,839 | |
Thereafter | 4,597 | |
Total | $ 16,426 | $ 17,975 |
Derivative Financial Instrume_3
Derivative Financial Instruments and Hedging Activities (Details) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 USD ($) derivative | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) derivative | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Derivatives, Fair Value | |||||
Derivatives expected to be reclassified in the next 12 months | $ 5,600,000 | $ 5,600,000 | |||
Derivative financial instruments - interest rate swaps | 7,721,000 | 7,721,000 | $ 0 | ||
Liability Derivatives | 0 | 0 | 5,069,000 | ||
Fair value of derivatives in net asset position, including accrued interest, excluding nonperformance risk adjustment | $ 7,800,000 | $ 7,800,000 | |||
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | |||||
Derivatives, Fair Value | |||||
Number of instruments | derivative | 7 | 7 | |||
Notional amount | $ 500,000,000 | $ 500,000,000 | |||
Gain (loss) recognized in OCI | 3,255,000 | $ (150,000) | 10,473,000 | $ 1,013,000 | |
Gain (loss) reclassified from accumulated OCI into income | (830,000) | $ (1,673,000) | (2,429,000) | $ (3,302,000) | |
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Receivables and other assets | |||||
Derivatives, Fair Value | |||||
Derivative financial instruments - interest rate swaps | 7,721,000 | 7,721,000 | 0 | ||
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Derivative financial instruments | |||||
Derivatives, Fair Value | |||||
Liability Derivatives | $ 0 | $ 0 | $ 5,069,000 |
Commitments and Contingencies (
Commitments and Contingencies (Details) | May 02, 2022 defendant |
Shiva Stein v. Healthcare Trust of America, Inc., et al. | |
Loss Contingencies [Line Items] | |
Number of defendants | 2 |
Partners' Capital - Narrative (
Partners' Capital - Narrative (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||||
Jul. 06, 2022 $ / shares | Jul. 01, 2022 $ / shares | Jun. 30, 2022 USD ($) $ / shares shares | Mar. 31, 2022 $ / shares | Jun. 30, 2021 USD ($) $ / shares | Mar. 31, 2021 $ / shares | Jun. 30, 2022 USD ($) shares | Jun. 30, 2021 USD ($) | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Dividend distribution ratio | 1 | |||||||
Distributions declared, but not paid | $ | $ 75,765 | $ 71,302 | $ 75,765 | $ 71,302 | ||||
Common stock dividends declared (in dollars per share) | $ 0.325 | $ 0.325 | $ 0.320 | $ 0.320 | ||||
Subsequent Event | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Common stock dividends declared (in dollars per share) | $ 4.82 | $ 0.029 | ||||||
Operating Partnership distributions paid (in dollars per share) | 4.82 | $ 0.029 | ||||||
Distributions paid (in dollars per share) | $ 4.82 | |||||||
Restricted Common Stock | ||||||||
Incentive Plan | ||||||||
Nonvested awards, total compensation cost not yet recognized | $ | $ 6,200 | $ 6,200 | ||||||
Period for recognition (in years) | 1 year 7 months 6 days | |||||||
Restricted Common Stock | Minimum | ||||||||
Incentive Plan | ||||||||
Award vesting period | 3 years | |||||||
Restricted Common Stock | Maximum | ||||||||
Incentive Plan | ||||||||
Award vesting period | 4 years | |||||||
Restricted Common Stock | General and Administrative Expense | ||||||||
Incentive Plan | ||||||||
Compensation expense | $ | $ 2,200 | $ 2,100 | $ 4,200 | $ 5,400 | ||||
Amended and Restated 2006 Incentive Plan | ||||||||
Incentive Plan | ||||||||
Number of shares authorized (in shares) | shares | 10,000,000 | 10,000,000 | ||||||
Number of shares available for grant (in shares) | shares | 9,647,839 | 9,647,839 |
Partners' Capital - Restricted
Partners' Capital - Restricted Common Stock Activity (Details) - Restricted Common Stock - $ / shares | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Restricted Common Stock | ||
Balance as of beginning of period (in shares) | 529,862 | 436,399 |
Granted (in shares) | 158,543 | 354,288 |
Vested (in shares) | (124,407) | (270,099) |
Forfeited (in shares) | (7,690) | (6,767) |
Balance as of end of period (in shares) | 556,308 | 513,821 |
Weighted Average Grant Date Fair Value | ||
Balance as of beginning of period (in dollars per share) | $ 28.83 | $ 28.27 |
Granted (in dollars per share) | 30.81 | 26.62 |
Vested (in dollars per share) | 27.37 | 27.48 |
Forfeited (in dollars per share) | 29.58 | 28.87 |
Balance as of end of period (in dollars per share) | $ 29.71 | $ 27.54 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Assets: | ||
Real estate notes receivable, net | $ 75,872 | $ 69,114 |
Derivative financial instruments | 7,721 | 0 |
Liabilities: | ||
Derivative financial instruments | 0 | 5,069 |
Debt | 3,094,643 | 3,028,122 |
Fair Value, Measurements, Recurring | Carrying Amount | Level 2 | ||
Assets: | ||
Real estate notes receivable, net | 75,872 | 69,114 |
Derivative financial instruments | 7,721 | 0 |
Liabilities: | ||
Derivative financial instruments | 0 | 5,069 |
Debt | 3,094,643 | 3,028,122 |
Fair Value, Measurements, Recurring | Fair Value | Level 2 | ||
Assets: | ||
Real estate notes receivable, net | 72,377 | 68,476 |
Derivative financial instruments | 7,721 | 0 |
Liabilities: | ||
Derivative financial instruments | 0 | 5,069 |
Debt | $ 2,797,099 | $ 3,117,602 |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments - Assets Measured on Non-Recurring Basis (Details) - Fair Value, Nonrecurring - Fair Value - MOB - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Level 2 | ||
Assets: | ||
Real estate investment | $ 0 | $ 26,768 |
Level 3 | ||
Assets: | ||
Real estate investment | $ 0 | $ 4,970 |
Per Unit Data (Details)
Per Unit Data (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Numerator: | ||||||
Net income | $ 14,422 | $ 38,739 | $ 33,088 | $ 61,132 | ||
Net income attributable to non-controlling interests | 0 | 0 | 0 | 0 | ||
Net income attributable to common stockholders/unitholders | $ 14,422 | $ 18,666 | $ 38,739 | $ 22,393 | $ 33,088 | $ 61,132 |
Denominator: | ||||||
Weighted average OP Units outstanding - basic (in shares) | 233,125 | 222,326 | 233,086 | 222,297 | ||
Dilutive units - OP Units convertible into common units (in shares) | 0 | 0 | 0 | 0 | ||
Adjusted weighted average units outstanding - diluted (in shares) | 233,125 | 222,326 | 233,086 | 222,297 | ||
Earnings per common unit - basic: | ||||||
Net income attributable to common unitholders (in dollars per share) | $ 0.06 | $ 0.17 | $ 0.14 | $ 0.28 | ||
Earnings per common unit - diluted: | ||||||
Net income attributable to common unitholders (in dollars per share) | $ 0.06 | $ 0.17 | $ 0.14 | $ 0.28 |
Supplemental Cash Flow Inform_3
Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Supplemental Disclosure of Cash Flow Information: | ||
Interest paid, net of capitalized interest | $ 50,284 | $ 39,827 |
Cash paid for operating leases | 7,609 | 7,942 |
Supplemental Disclosure of Noncash Investing and Financing Activities: | ||
Accrued capital expenditures | 6,244 | 13,065 |
Distributions declared, but not paid | 75,765 | 71,302 |
ROU assets obtained in exchange for lease obligations | $ 705 | $ 7,683 |
Subsequent Events - Narrative (
Subsequent Events - Narrative (Details) | 2 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||||
Jul. 06, 2022 $ / shares | Jul. 01, 2022 $ / shares | Aug. 18, 2022 USD ($) building | Jun. 30, 2022 USD ($) $ / shares | Mar. 31, 2022 $ / shares | Jun. 30, 2021 $ / shares | Mar. 31, 2021 $ / shares | Jun. 30, 2022 USD ($) | Jul. 20, 2022 USD ($) extension_option $ / shares | May 31, 2022 USD ($) | May 13, 2022 USD ($) | Dec. 31, 2021 USD ($) | Oct. 06, 2021 USD ($) | Dec. 31, 2018 USD ($) | |
Subsequent Event [Line Items] | ||||||||||||||
Outstanding amount | $ 3,115,000,000 | $ 3,115,000,000 | $ 3,050,000,000 | |||||||||||
Common stock dividends declared (in dollars per share) | $ / shares | $ 0.325 | $ 0.325 | $ 0.320 | $ 0.320 | ||||||||||
Senior Notes | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Extinguishment of debt | 700,000,000 | |||||||||||||
Outstanding amount | $ 2,550,000,000 | 2,550,000,000 | 2,550,000,000 | |||||||||||
Line of Credit | Unsecured revolving credit facility | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Line of credit facility, borrowing capacity | $ 1,000,000,000 | |||||||||||||
Unsecured term loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Line of credit facility, borrowing capacity | $ 300,000,000 | |||||||||||||
Outstanding amount | 500,000,000 | 500,000,000 | $ 500,000,000 | |||||||||||
$300.0 Million Unsecured Term Loan due 2023 | Unsecured term loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Outstanding amount | 300,000,000 | 300,000,000 | ||||||||||||
Term Loan Agreement | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Outstanding amount | $ 1,125,000,000 | $ 1,125,000,000 | ||||||||||||
$200.0 Million Unsecured Term Loan due 2024 | Unsecured term loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | 200,000,000 | 200,000,000 | $ 200,000,000 | |||||||||||
Outstanding amount | $ 200,000,000 | $ 200,000,000 | ||||||||||||
Subsequent Event | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.01 | |||||||||||||
Common stock dividends declared (in dollars per share) | $ / shares | $ 4.82 | $ 0.029 | ||||||||||||
Sale of joint ventures and assets | $ 433,000,000 | |||||||||||||
Subsequent Event | Building | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Number of MOBs acquired | building | 6 | |||||||||||||
Payments to acquire MOB's | $ 65,500,000 | |||||||||||||
Subsequent Event | Line of Credit | Unsecured revolving credit facility | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Line of credit facility, borrowing capacity | $ 1,500,000,000 | |||||||||||||
Subsequent Event | Senior Notes due 2025 | Senior Notes | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 250,000,000 | |||||||||||||
Debt instrument, stated interest rate | 3.875% | |||||||||||||
Subsequent Event | Senior Notes due 2028 | Senior Notes | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 300,000,000 | |||||||||||||
Debt instrument, stated interest rate | 3.625% | |||||||||||||
Subsequent Event | Senior Notes due 2030 | Senior Notes | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 300,000,000 | |||||||||||||
Debt instrument, stated interest rate | 2.40% | |||||||||||||
Subsequent Event | Senior Notes due 2031 | Senior Notes | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 300,000,000 | |||||||||||||
Debt instrument, stated interest rate | 2.05% | |||||||||||||
Subsequent Event | Term Facility One | Term Loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 200,000,000 | |||||||||||||
Number of extension options | extension_option | 2 | |||||||||||||
Term of extension option | 1 year | |||||||||||||
Subsequent Event | Term Facility Two | Term Loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 150,000,000 | |||||||||||||
Subsequent Event | Healthcare Trust of America Holdings, LP (HTALP) | $300.0 Million Unsecured Term Loan due 2023 | Unsecured term loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Outstanding amount | 300,000,000 | |||||||||||||
Subsequent Event | Healthcare Trust of America Holdings, LP (HTALP) | Delayed-Draw Term Loan Facility, Due July 2023 | Unsecured term loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 350,000,000 | |||||||||||||
Number of extension options | extension_option | 2 | |||||||||||||
Term of extension option | 1 year | |||||||||||||
Subsequent Event | Healthcare Trust of America Holdings, LP (HTALP) | Term Loan Facility, Due January 20, 2028 | Unsecured term loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 300,000,000 | |||||||||||||
Subsequent Event | Healthcare Trust of America Holdings, LP (HTALP) | $200.0 Million Unsecured Term Loan due 2024 | Unsecured term loans | ||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||
Debt instrument, face amount | $ 200,000,000 |
Subsequent Events - Results of
Subsequent Events - Results of Exchange Offers (Details) - Subsequent Event - Unsecured senior notes $ in Thousands | Jul. 20, 2022 USD ($) |
Senior Notes due 2025 | |
Subsequent Event [Line Items] | |
Debt instrument, stated interest rate | 3.875% |
Tenders and Consents Received as of the Expiration Date | $ 235,016 |
Percentage of Total Outstanding Principal Amount of Such Series of Old HR Notes | 94.01% |
Senior Notes due 2028 | |
Subsequent Event [Line Items] | |
Debt instrument, stated interest rate | 3.625% |
Tenders and Consents Received as of the Expiration Date | $ 290,246 |
Percentage of Total Outstanding Principal Amount of Such Series of Old HR Notes | 96.75% |
Senior Notes due 2030 | |
Subsequent Event [Line Items] | |
Debt instrument, stated interest rate | 2.40% |
Tenders and Consents Received as of the Expiration Date | $ 297,507 |
Percentage of Total Outstanding Principal Amount of Such Series of Old HR Notes | 99.17% |
Senior Notes due 2031 | |
Subsequent Event [Line Items] | |
Debt instrument, stated interest rate | 2.05% |
Tenders and Consents Received as of the Expiration Date | $ 298,858 |
Percentage of Total Outstanding Principal Amount of Such Series of Old HR Notes | 99.62% |